{"gene":"SMAD2","run_date":"2026-06-10T07:46:35","timeline":{"discoveries":[{"year":1996,"finding":"MADR2/SMAD2 is directly phosphorylated by the TGF-β receptor complex on C-terminal serines. Interaction requires activation of receptor I (TβRI) by receptor II (TβRII), mediated by the receptor I kinase. Mutation of the phosphorylation sites generates a dominant-negative MADR2 that stably associates with receptors and fails to accumulate in the nucleus in response to TGF-β.","method":"In vitro phosphorylation assay, dominant-negative mutagenesis, nuclear accumulation assay, co-immunoprecipitation with receptors","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro phosphorylation by receptor complex, mutagenesis of phosphorylation sites, functional readout of nuclear accumulation and transcription; replicated across multiple experimental approaches in a landmark paper","pmids":["8980228"],"is_preprint":false},{"year":1996,"finding":"MADR2/SMAD2 is specifically regulated by TGF-β and not bone morphogenetic proteins. Missense mutations found in colorectal carcinomas are inactivating for TGF-β signaling.","method":"Biochemical signaling assays, functional analysis of cancer-derived point mutations","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical specificity demonstrated, functional inactivation of cancer-derived mutations confirmed, replicated concept across multiple labs","pmids":["8752209"],"is_preprint":false},{"year":1996,"finding":"Madr2/SMAD2 is a mesoderm inducer that responds to activin signaling; activin stimulation enhances nuclear concentration of Madr2 in Xenopus ectoderm. The C-terminal domain can activate downstream components independently, while an N-terminal repressive domain anchors the protein in the cytoplasm in the absence of signal.","method":"Xenopus ectoderm functional assay, lacZ/Madr2 fusion protein nuclear localization analysis, domain deletion experiments","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiment tied to functional consequence (mesoderm induction), domain dissection experiment, activin-dependent nuclear translocation shown","pmids":["8756346"],"is_preprint":false},{"year":1997,"finding":"Smad2 and Smad3 interact with the kinase-deficient TGF-β type I receptor after it is phosphorylated by TβRII kinase. TGF-β1 induces phosphorylation of Smad2 and Smad3, and Smads 2 and 3 form heteromeric complexes with Smad4 after TβR activation. Smad2, Smad3 and Smad4 accumulate in the nucleus upon TGF-β1 treatment and show synergistic effects in transcriptional reporter assays.","method":"Co-immunoprecipitation in transfected COS cells, immunofluorescence nuclear localization, transcriptional reporter assay (PAI-1 promoter), dominant-negative Smad3","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, nuclear translocation imaging, functional transcriptional readout, dominant-negative epistasis, replicated across multiple cell lines","pmids":["9311995"],"is_preprint":false},{"year":1998,"finding":"SARA (Smad anchor for receptor activation), a FYVE domain protein, directly interacts with Smad2 and Smad3 and recruits Smad2 to the TGF-β receptor by controlling subcellular localization. Phosphorylation of Smad2 induces dissociation from SARA with concomitant Smad2/Smad4 complex formation and nuclear translocation. SARA mutations causing mislocalization of Smad2 inhibit TGF-β-dependent transcriptional responses.","method":"Yeast two-hybrid/pulldown, co-immunoprecipitation, subcellular localization assay, dominant-negative SARA mutant functional assay, transcriptional reporter assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding demonstrated, localization-function linkage established by mislocalization mutant, phosphorylation-driven complex switching shown, multiple orthogonal methods","pmids":["9865696"],"is_preprint":false},{"year":1998,"finding":"HGF and EGF, signaling through receptor tyrosine kinases, can also induce phosphorylation and nuclear translocation of Smad2 via kinase(s) downstream of MEK1. A mutation in Smad2 that blocks TGF-β signaling also blocks HGF signal transduction, placing Smad2 as a common effector of both RTK and TGF-β receptor pathways.","method":"Epitope-tagged Smad2 phosphorylation and nuclear translocation assay, SMAD-dependent reporter gene activation, dominant-negative Smad2 epistasis","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — nuclear translocation and reporter assay in single lab, functional mutation epistasis shown; replicated in part but pathway placement is via single mutation","pmids":["9620846"],"is_preprint":false},{"year":1999,"finding":"SMAD2 is required in extraembryonic tissues for generation of the anterior-posterior axis and gastrulation. Postgastrulation Smad2-deficient embryos show malformation of head structures, abnormal embryo turning, and cyclopia, and expression of the homeobox gene Hex (earliest A-P polarity marker) is absent in Smad2-deficient embryos.","method":"Smad2 null mouse knockout, chimeric embryo rescue by wild-type extraembryonic tissues, in situ hybridization for Hex expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function in vivo with defined molecular readout (Hex expression), tissue-specific rescue experiment, multiple developmental phenotypes characterized","pmids":["10535967"],"is_preprint":false},{"year":2000,"finding":"Calmodulin directly binds to two distinct conserved regions in Smad2 and inhibits Smad2 function in Xenopus embryos. Calmodulin binding to Smad2 inhibits subsequent Erk2-dependent linker region phosphorylation of Smad2, and vice versa, indicating cross-talk between Ca2+/calmodulin, RTK/Erk, and TGF-β pathways at the level of Smad2.","method":"Direct binding assay (calmodulin-Smad interaction), Xenopus embryo functional assay, structure-function analysis with domain deletions, Erk2-dependent phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated, functional inhibition in vivo, cross-talk mechanism via phosphorylation shown; single lab with multiple methods","pmids":["11007779"],"is_preprint":false},{"year":2004,"finding":"Smad2 and Smad3 function cooperatively in craniofacial and endodermal development. Compound heterozygous mice (one allele each of Smad2 and Smad3 null) show craniofacial defects and hepatic phenotypes due to defects in the definitive endoderm, including failure to displace visceral endoderm.","method":"Genetic epistasis via compound heterozygous mouse knockout, histology, gene expression analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with defined tissue-specific readout, compound heterozygous rescue and phenotyping","pmids":["15183723"],"is_preprint":false},{"year":2006,"finding":"Smad2 acetylation by coactivators p300, CBP, and P/CAF occurs in a TGF-β-dependent manner. The major acetylated residue in both the long and short isoforms of Smad2 is Lys19 in the MH1 domain. Acetylation of Lys19 in the short isoform improves DNA binding activity in vitro, enhances association with target promoters in vivo, and augments transcriptional activity by inducing a conformational change making the DNA-binding domain accessible.","method":"In vitro acetylation assay, acetyl-Lys19-specific antibody detection of endogenous acetylation, chromatin immunoprecipitation (ChIP), site-directed mutagenesis of Lys19, DNA binding assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic acetylation by named writers (p300, CBP, P/CAF), mutagenesis of the modified residue, endogenous modification confirmed, ChIP for promoter binding, conformational change mechanistically supported","pmids":["17074756"],"is_preprint":false},{"year":2007,"finding":"Endoglin increases Smad2 protein levels by decreasing ubiquitination and proteasome-dependent degradation, thereby stabilizing Smad2 and potentiating TGF-β-Smad2 signaling to increase eNOS expression in endothelial cells. Smad2-specific signaling is upregulated by endoglin and downregulated when endoglin is knocked down with siRNA.","method":"siRNA knockdown of endoglin, dominant-negative Smad2, ubiquitination assay, Western blot for Smad2 protein levels vs. mRNA, eNOS and PAI-promoter reporter assay","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination/degradation mechanism demonstrated, promoter reporter assays, siRNA knockdown; single lab, multiple methods","pmids":["17058229"],"is_preprint":false},{"year":2009,"finding":"Smad2 and Smad3 are transcription factors downstream of myostatin/TGF-β that induce a muscle atrophy program in adult myofibers. Smad2/3 inhibition promotes muscle hypertrophy in a manner independent of satellite cells but partially dependent on mTOR signaling.","method":"In vivo genetic perturbation with dominant-negative constructs in adult myofibers, muscle mass measurement, mTOR signaling analysis","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function with defined atrophy/hypertrophy phenotype, pathway epistasis with mTOR; single lab","pmids":["19357234"],"is_preprint":false},{"year":2010,"finding":"Smad2 protects against TGF-β/Smad3-mediated renal fibrosis. Conditional deletion of Smad2 from kidney tubular epithelial cells markedly enhanced fibrosis, and Smad2 deletion promoted fibrosis through enhanced TGF-β/Smad3 signaling evidenced by greater Smad3 phosphorylation, nuclear translocation, and binding of Smad3 to the COL1A2 promoter. Conversely, overexpression of Smad2 attenuated TGF-β1-induced Smad3 phosphorylation.","method":"Conditional Smad2 knockout in tubular epithelial cells (unilateral ureteral obstruction model), Smad2 overexpression, Smad3 ChIP on COL1A2 promoter, Western blot for phospho-Smad3","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined molecular mechanism (Smad3 phosphorylation and ChIP-promoter binding), overexpression reciprocal experiment, in vivo and in vitro orthogonal validation","pmids":["20595680"],"is_preprint":false},{"year":2013,"finding":"Araf kinase directly binds to and phosphorylates Smad2 in the linker region with Ser253 being indispensable, in a Mek/Erk-independent manner. This linker phosphorylation attenuates Smad2 signaling by accelerating degradation of activated Smad2 and antagonizes mesendoderm induction by Nodal/Smad2 in zebrafish embryos.","method":"Direct in vitro kinase assay (Araf phosphorylates Smad2), site-directed mutagenesis of S253, co-immunoprecipitation (Araf-Smad2 interaction), zebrafish araf knockdown with mesendoderm phenotype, degradation assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis identifying specific phosphorylation site, direct binding, in vivo loss-of-function epistasis, degradation mechanism shown","pmids":["23591895"],"is_preprint":false},{"year":2013,"finding":"PAK4 interacts with Smad2/3 in a kinase-independent manner and blocks TGF-β1-induced phosphorylation of Smad2 at Ser465/467, attenuating Smad2/3 transcriptional activity. Additionally, PAK4 phosphorylates Smad2 on Ser465 in a kinase-dependent manner under HGF stimulation, leading to ubiquitin-proteasome-dependent degradation of Smad2.","method":"Co-immunoprecipitation (PAK4-Smad2/3 interaction), kinase assay, dominant-negative and constitutively active PAK4 constructs, ubiquitin-proteasome degradation assay, immunohistochemistry of gastric cancer tissues","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction and kinase activity shown, two distinct mechanisms (kinase-independent blocking and kinase-dependent phosphorylation/degradation) demonstrated; single lab","pmids":["23934187"],"is_preprint":false},{"year":2015,"finding":"Smad2 negatively regulates TGF-β autoinduction in dendritic cells, whereas Smad3 is necessary for robust TGF-β expression. Smad2-deficient DCs expressed higher concentrations of TGF-β and were tolerogenic for colitis models.","method":"Smad2-deficient dendritic cells (conditional knockout), TGF-β expression assay, colitis model","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined molecular and cellular phenotype; single lab with in vitro and in vivo validation","pmids":["26141582"],"is_preprint":false},{"year":2016,"finding":"Smad2 and Smad3 regulate chondrocyte proliferation and differentiation in the growth plate by repressing Ihh expression. Smad2 and Smad3 bind to distinct Smad binding elements (SBEs) in the Ihh promoter, mediating assembly of distinct repressive complexes: TGF-β induces association of Hdac4 with Smad2 (but not Smad3) on the Ihh promoter, while Ski is recruited by Smad3.","method":"Cartilage-specific Smad2 conditional KO and global Smad3 KO mice, ChIP analysis of Smad2/3 and Hdac4 on Ihh promoter, SBE mutagenesis, primary chondrocyte TGF-β treatment","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with phenotype, ChIP demonstrating differential Smad2/3 binding at specific SBEs, SBE mutagenesis, corepressor association defined by ChIP; multiple orthogonal methods","pmids":["27741240"],"is_preprint":false},{"year":2016,"finding":"Smad3 preferentially localizes to the nucleus in unstimulated cells (sequestered from membrane signaling), while Smad2 remains predominantly cytoplasmic and is a more sensitive TGF-β transducer. The unique linker region of Smad3 impairs its ability to oligomerize with Smad4 upon agonist stimulation.","method":"Subcellular fractionation, immunofluorescence localization, Smad4 co-immunoprecipitation assay, ChIP-seq for target gene binding specificity","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence, oligomerization assay; single lab, multiple methods","pmids":["26905010"],"is_preprint":false},{"year":2016,"finding":"Smad2/3 proteins are required for immobilization-induced skeletal muscle atrophy. Immobilization elevates Smad2/3 protein (not mRNA) levels in muscle. Muscle-specific Smad2/3-deficient mice are significantly resistant to denervation-induced atrophy, and expression of atrogenes Atrogin-1 and MuRF1 does not increase in Smad2/3-deficient muscles following denervation. IGF1 signaling inhibits Smad2/3 protein accumulation.","method":"Muscle-specific Smad2/3 double knockout mice, denervation/immobilization model, atrogene expression analysis, IGF1 receptor activity assessment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific double KO with defined atrophy phenotype, molecular mechanism (atrogene induction) established, protein vs. mRNA distinction made; multiple in vivo and in vitro experiments","pmids":["27129272"],"is_preprint":false},{"year":2017,"finding":"CCT6A directly binds SMAD2 and suppresses its function, switching TGF-β-induced transcriptional responses from tumor-suppressive (Smad2-dependent) to prometastatic (Smad3-dependent) in NSCLC cells.","method":"Co-immunoprecipitation (CCT6A-SMAD2 direct interaction), SMAD2/CCT6A knockdown, transcriptional response assay, NSCLC cell invasion/metastasis assay","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding confirmed by co-IP, SMAD2 functional suppression by CCT6A shown; single lab, multiple cell/animal models","pmids":["28375158"],"is_preprint":false},{"year":2017,"finding":"Fibroblast-specific deletion of Smad3, but not Smad2, markedly reduces pressure overload-induced cardiac fibrosis. Deletion of Smad2/3 from tissue-resident fibroblasts attenuates injury-induced cellular expansion and expression of fibrosis-mediating genes.","method":"Fibroblast- and myofibroblast-specific inducible Cre knockout mice for Smad2 or Smad3, pressure overload model, fibrosis quantification, gene expression analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with defined in vivo fibrosis phenotype; Smad2 vs. Smad3 dissected; replicated across fibrosis models","pmids":["28891814"],"is_preprint":false},{"year":2018,"finding":"The crystal structures of SMAD3 in complex with FOXH1 and SMAD2 in complex with corepressor SKI reveal that the MH2 domains of SMAD2 and SMAD3 have multiple hydrophobic patches on their surfaces that serve as cofactor interaction interfaces. Cofactors tether to various subsets of these patches in a cooperative or competitive manner to control TGF-β signaling output.","method":"X-ray crystallography of SMAD3-FOXH1 complex and SMAD2-SKI complex, structural analysis of MH2 hydrophobic patches","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures of SMAD2-SKI and SMAD3-FOXH1 complexes, structural basis for differential cofactor binding defined","pmids":["29588413"],"is_preprint":false},{"year":2019,"finding":"Biochemical and structural evidence shows that SMAD2 binding to DNA depends on the conformation of the E3 insert (a structural element unique to SMAD2 previously thought to render SMAD2 unable to bind DNA). SMAD2 remains predominantly cytoplasmic in the basal state and binds SMAD4 upon Nodal TGF-β signaling to join SMAD3:FOXH1 at target promoters. SMAD3 is recruited by FOXH1 to mesendoderm differentiation gene promoters independently of TGF-β signals, while SMAD2 requires signaling.","method":"Crystal structure of SMAD2-DNA complex, biochemical DNA binding assay, ChIP-seq for SMAD2 and SMAD3 binding at mesendoderm promoters, SMAD3 and FOXH1 co-IP, mouse mesendoderm differentiation genetic experiments","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with E3 insert conformation, biochemical DNA binding assay, ChIP-seq for in vivo binding, genetic in vivo validation; multiple orthogonal methods","pmids":["31582430"],"is_preprint":false},{"year":2019,"finding":"WWP2 (E3 ubiquitin ligase, N-terminal isoform) interacts with SMAD2 and mediates TGF-β1-induced nucleocytoplasmic shuttling and transcriptional activity of SMAD2. TGF-β1 stimulation promotes nuclear translocation of WWP2 N-terminal isoforms and their interaction with SMAD2.","method":"Co-immunoprecipitation of WWP2-SMAD2, nuclear translocation assay, transgenic mouse with WWP2 N-terminal deletion (reduced cardiac fibrosis), primary cardiac fibroblast assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction by co-IP, nuclear translocation shown, in vivo KO phenotype; single lab with multiple orthogonal methods","pmids":["31399586"],"is_preprint":false},{"year":2020,"finding":"SIRT2 directly interacts with and deacetylates SMAD2 at lysine 451, promoting its ubiquitination and degradation. Loss of SMAD specific E3 ubiquitin protein ligase 2 (SMURF2) abolishes SIRT2-induced ubiquitination and degradation of SMAD2. SIRT2 also reduces phosphorylation, acetylation and nuclear localization of SMAD2.","method":"Co-immunoprecipitation, in vitro deacetylation assay with site identification (K451), ubiquitination assay, SMURF2 knockdown epistasis, conditional Sirt2 KO in renal tubule epithelial cells","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical deacetylation with specific lysine identified, ubiquitination mechanism and E3 ligase (SMURF2) identified, in vivo KO phenotype corroborates; multiple orthogonal methods","pmids":["37777567"],"is_preprint":false},{"year":2020,"finding":"LSD1 is recruited together with phosphorylated SMAD2/3 to promoters of TGF-β1-activated and repressed EMT genes within 30-90 minutes of TGF-β1 treatment, triggering a nuclear oxidative wave. This LSD1-pSMAD2/3 complex primes TGF-β1/EMT target genes for activation or repression through targeted DNA oxidation.","method":"ChIP (LSD1 and pSMAD2/3 co-recruitment to promoters), confocal microscopy and mass spectrometry for nuclear oxidative wave, co-immunoprecipitation","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for co-recruitment at promoters, mass spectrometry for DNA oxidation; single lab, multiple methods","pmids":["32697292"],"is_preprint":false},{"year":2020,"finding":"SMAD2 interacts with MED1 and MED1 downregulation protects SMAD2 from ubiquitin-mediated degradation, stabilizing SMAD2 and promoting TGF-β/SMAD2-dependent EMT and metastasis in cutaneous melanoma.","method":"Co-immunoprecipitation (MED1-SMAD2 interaction), ubiquitination assay, MED1 knockdown/overexpression with EMT and migration readouts, in vivo metastasis model","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction and ubiquitination mechanism shown; single lab, in vitro and in vivo validation","pmids":["35131256"],"is_preprint":false},{"year":2021,"finding":"Creatine promotes cancer metastasis by activating monopolar spindle 1 (MPS1)-mediated phosphorylation of Smad2 and Smad3, leading to upregulation of Snail and Slug expression. MPS1 inhibition suppresses cancer metastasis by downregulating Smad2/3 phosphorylation and downstream Snail/Slug.","method":"MPS1 inhibitor treatment, GATM knockdown, Smad2/3 phosphorylation western blot, orthotopic mouse metastasis models","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic inhibition of MPS1 with Smad2/3 phosphorylation readout, in vivo metastasis model; single lab","pmids":["33811821"],"is_preprint":false},{"year":2021,"finding":"In the absence of TGF-β signaling, SMAD2 promotes terminal myogenic differentiation and myogenin expression in a TGF-β receptor-independent manner. Knockout of SMAD2 in primary myoblasts produces smaller myotubes with reduced myogenin expression; loss of Smad2 in satellite cells in vivo results in decreased muscle fiber caliber and impaired regeneration.","method":"SMAD2 knockout in primary myoblasts, SMAD2 overexpression (signaling-independent constructs), in vivo satellite cell-specific Smad2 KO, muscle regeneration assay","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO and overexpression with defined molecular (myogenin expression) and cellular (myotube size) phenotype, both in vitro and in vivo; single lab","pmids":["33462116"],"is_preprint":false},{"year":2021,"finding":"Mitochondrial dysfunction induces MAPKs-mediated phosphorylation of SMAD2 at a mitochondrial localization, leading to enhanced ALK5-SMAD2 signaling in endothelial cells. Genetic deficiency of SMAD2 prevents retinal vessel growth retardation and arteriovenous malformations in mitochondria-deficient mutant mice.","method":"Endothelial-specific SMAD2 KO mice, TFAM/COX10/TRX2 endothelial KO models, ALK5 pharmacological inhibition, SMAD2 phosphorylation localization by cell fractionation","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO of SMAD2 rescues vascular phenotype across three independent mitochondrial KO models; mechanism (MAPK-mediated mitochondrial SMAD2 phosphorylation) proposed with partial biochemical support; single lab","pmids":["36496409"],"is_preprint":false},{"year":2021,"finding":"Low fluid shear stress activates Smad2/3 phosphorylation through ALK5 and Neuropilin-1 (which increases sensitivity to BMP-9). Smad2/3 nuclear translocation and target gene expression (but not phosphorylation) are maximal at low FSS and suppressed at physiological high shear. The MEKK3/Klf2 pathway mediates suppression of Smad2/3 nuclear translocation at high FSS through CDK2-dependent phosphorylation of the Smad linker region.","method":"EC-specific ALK5 deletion in carotid ligation model, nuclear translocation immunofluorescence, pharmacological CDK2/Klf2 inhibition, in vitro flow chamber experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EC-specific KO with in vivo vascular phenotype, CDK2-linker phosphorylation mechanism identified; single lab, multiple methods","pmids":["34504019"],"is_preprint":false},{"year":2018,"finding":"Individual phosphorylation sites in the Smad2 linker region (Thr220, Ser245, Ser250, Ser255) are selectively phosphorylated by different kinases (JNK, p38, PI3K for Thr220; multiple kinases for serine residues) in response to thrombin, and are linked to the expression of specific proteoglycan/glycosaminoglycan synthesis genes (XT-1, C4ST-1, CHSY-1).","method":"Site-directed mutagenesis of individual linker region residues, selective kinase inhibitors, gene expression analysis for GAG synthesis genes","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific residue-kinase linkages defined by mutagenesis and selective inhibitors; single lab, multiple phospho-site/kinase combinations analyzed","pmids":["30423352"],"is_preprint":false},{"year":2015,"finding":"Smad2, but not Smad3, acts as a transcriptional repressor upstream of the BECN1 promoter in endothelial cells, regulating autophagy. Endoglin promotes autophagy by impeding Smad2 transcriptional repressor activity, with Smad2 knockdown directly correlating with enhanced beclin1 levels and autophagy.","method":"Smad2 siRNA knockdown, BECN1 promoter reporter assay, endoglin overexpression/knockdown, autophagy quantification","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assay identifies SMAD2 as repressor, siRNA knockdown with autophagy readout; single lab, multiple methods","pmids":["25931117"],"is_preprint":false},{"year":2020,"finding":"Mutant FOXL2C134W acquires the ability to bind SMAD4 and form a FOXL2C134W/SMAD4/SMAD2/3 complex that binds a novel hybrid DNA motif unique to the mutant. Ablation of SMAD4 or SMAD2/3 strongly reduces FOXL2C134W binding at hybrid sites and decreases expression of associated EMT genes.","method":"Co-immunoprecipitation (FOXL2C134W-SMAD4-SMAD2/3 complex), ChIP-seq for hybrid motif binding, siRNA knockdown of SMAD4 and SMAD2/3, chromatin state analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complex formation by co-IP, ChIP-seq for binding sites, knockdown epistasis; single lab, multiple orthogonal methods","pmids":["32641411"],"is_preprint":false},{"year":2023,"finding":"PPM1A (protein phosphatase magnesium-dependent 1A) directly interacts with phospho-SMAD2 and acts as a phosphatase for SMAD2. PPM1A knockout protects mice from cartilage degeneration in the DMM model by maintaining higher p-SMAD2 levels in chondrocytes; inhibition of TGF-β/SMAD2 signaling (by SD-208) abolishes the protective phenotype of PPM1A-KO mice.","method":"Co-immunoprecipitation (PPM1A-pSMAD2 interaction), PPM1A conditional KO mouse with DMM model, pharmacological rescue with SD-208 (TGF-β/SMAD2 inhibitor), PPM1A pharmacological inhibitors (SC, BC-21)","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct interaction confirmed, conditional KO with in vivo phenotype, pharmacological rescue epistasis, PPM1A established as a SMAD2 phosphatase; multiple orthogonal methods","pmids":["36752205"],"is_preprint":false},{"year":2024,"finding":"Thbs1 activates TGF-β-Smad2/3 signaling which induces ATF4 expression; Smad2/3 together with ATF4 modulate the autophagy-lysosomal pathway (ALP) and ubiquitin-proteasome system (UPS) to facilitate muscle atrophy. Myofiber-specific deletion of Smad2 and Smad3 antagonizes Thbs1-induced muscle atrophy.","method":"Smad2/Smad3 myofiber-specific double KO mice, Thbs1 transgenic mice, ATF4 KO mice, ALP and UPS activity assays, Thbs1 KO denervation/caloric restriction models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific double KO with mechanistic pathway (Smad2/3→ATF4→ALP/UPS) defined, multiple genetic models, Thbs1 KO validation; multiple orthogonal in vivo experiments","pmids":["38678560"],"is_preprint":false}],"current_model":"SMAD2 is a receptor-regulated transcription factor that is directly phosphorylated on C-terminal serines by the activated TGF-β/activin type I receptor complex (requiring TβRI kinase activation by TβRII); in unstimulated cells, SARA (a FYVE-domain scaffold) anchors SMAD2 at the receptor by direct binding, while calmodulin and nuclear-preferring Smad3 compete for its regulation; upon receptor phosphorylation, SMAD2 dissociates from SARA, forms heterotrimeric complexes with SMAD4 (and SMAD3), and translocates to the nucleus, where its DNA binding is facilitated by a conformational change in its unique E3 insert and enhanced by p300/CBP/P/CAF-mediated acetylation of Lys19; nuclear SMAD2 recruits distinct co-activators (e.g., FOXH1 with SMAD4) or co-repressors (e.g., Hdac4 on the Ihh promoter) depending on context; its activity is attenuated by linker region phosphorylation (by Araf, MAPKs, CDK2), by phosphatases (PPM1A dephosphorylates it), by deacetylation/ubiquitination/degradation mediated by SIRT2/SMURF2, and by interactors such as CCT6A; SMAD2 and SMAD3 have distinct—sometimes opposing—roles in fibrosis (SMAD3 predominantly pro-fibrotic; SMAD2 counter-regulatory), muscle atrophy (both required downstream of myostatin/TGF-β and Thbs1 via ATF4/ALP/UPS), chondrogenesis, embryonic axis formation (Hex expression in extraembryonic tissue), and terminal myogenic differentiation (SMAD2 promotes myogenin independently of TGF-β receptor activation)."},"narrative":{"mechanistic_narrative":"SMAD2 is a receptor-regulated transcription factor that transduces TGF-β/activin/Nodal signals from the cell surface to the nucleus to control mesoderm induction, embryonic axis formation, and tissue homeostasis [PMID:8980228, PMID:8756346, PMID:10535967]. Upon activation of the TGF-β type I receptor by the type II receptor kinase, SMAD2 is directly phosphorylated on C-terminal serines; mutation of these sites yields a dominant-negative protein that stays receptor-bound and fails to accumulate in the nucleus [PMID:8980228, PMID:9311995]. In unstimulated cells SMAD2 is held cytoplasmic by the FYVE-domain scaffold SARA, which directly binds and recruits it to the receptor, while phosphorylation drives SARA dissociation, heterotrimer formation with SMAD4 (and SMAD3), and nuclear translocation [PMID:9865696, PMID:26905010]. In the nucleus, DNA binding depends on the conformation of the SMAD2-specific E3 insert and is enhanced by p300/CBP/P/CAF-mediated acetylation of Lys19 in the MH1 domain, while the MH2 hydrophobic surfaces serve as combinatorial docking sites for cofactors such as FOXH1 and the corepressor SKI [PMID:17074756, PMID:29588413, PMID:31582430]. SMAD2 activity is attenuated by linker-region phosphorylation (Araf, MAPKs, CDK2), by the phosphatase PPM1A, and by deacetylation and ubiquitin-mediated degradation through SIRT2/SMURF2 and interactors including CCT6A [PMID:23591895, PMID:34504019, PMID:36752205, PMID:37777567, PMID:28375158]. SMAD2 and SMAD3 carry distinct and often opposing roles: SMAD2 is counter-regulatory in fibrosis (restraining SMAD3-driven collagen induction), both are required for myostatin/TGF-β- and Thbs1-driven muscle atrophy via ATF4/ALP/UPS, and SMAD2 can promote terminal myogenic differentiation independently of receptor activation [PMID:20595680, PMID:28891814, PMID:38678560, PMID:33462116]. Cancer-derived inactivating mutations in SMAD2 abrogate TGF-β signaling, consistent with a tumor-suppressive role [PMID:8752209].","teleology":[{"year":1996,"claim":"Established SMAD2 as the direct intracellular substrate of the activated TGF-β receptor, defining the entry point of the signaling cascade.","evidence":"In vitro phosphorylation, dominant-negative mutagenesis of C-terminal serines, and nuclear accumulation assays","pmids":["8980228"],"confidence":"High","gaps":["Did not resolve heterotrimer composition or DNA-binding mechanism","Phosphatase/turnover regulation unaddressed"]},{"year":1996,"claim":"Defined pathway specificity (TGF-β vs BMP) and linked SMAD2 loss-of-function to human cancer through inactivating colorectal carcinoma mutations.","evidence":"Biochemical signaling specificity assays and functional analysis of cancer-derived point mutations","pmids":["8752209"],"confidence":"High","gaps":["Mechanism by which mutations inactivate signaling not structurally defined at the time"]},{"year":1996,"claim":"Showed SMAD2 is a signal-dependent mesoderm inducer whose nuclear accumulation rises with activin, with separable activating and cytoplasmic-anchoring domains.","evidence":"Xenopus ectoderm functional assay and lacZ-Madr2 nuclear localization with domain deletions","pmids":["8756346"],"confidence":"High","gaps":["Identity of the cytoplasmic anchor not yet known","Downstream transcriptional partners unidentified"]},{"year":1997,"claim":"Demonstrated heteromeric SMAD2/SMAD3/SMAD4 complex formation and cooperative nuclear transcriptional output, defining the effector complex.","evidence":"Reciprocal co-IP, immunofluorescence, and PAI-1 reporter assays with dominant-negative Smad3","pmids":["9311995"],"confidence":"High","gaps":["Stoichiometry of the complex not resolved","Promoter recruitment cofactors not identified"]},{"year":1998,"claim":"Identified SARA as the cytoplasmic anchor that recruits SMAD2 to the receptor, explaining how localization gates signaling.","evidence":"Yeast two-hybrid/pulldown, co-IP, mislocalization mutants, and reporter assays","pmids":["9865696"],"confidence":"High","gaps":["How phosphorylation releases SARA structurally unresolved","SARA regulation upstream not defined"]},{"year":1998,"claim":"Placed SMAD2 as a shared effector of RTK (HGF/EGF) signaling acting through MEK1-downstream kinases, broadening its input beyond TGF-β.","evidence":"Phosphorylation/nuclear translocation assays and dominant-negative epistasis","pmids":["9620846"],"confidence":"Medium","gaps":["Direct kinase downstream of MEK1 not identified","Physiological relevance vs canonical TGF-β input unclear"]},{"year":1999,"claim":"Established an in vivo developmental requirement for SMAD2 in extraembryonic tissue for A-P axis formation, linking it to Hex expression.","evidence":"Smad2 null mouse knockout, chimeric rescue, and Hex in situ hybridization","pmids":["10535967"],"confidence":"High","gaps":["Direct transcriptional targets driving axis formation not defined","Cell-autonomous vs non-autonomous contributions only partly resolved"]},{"year":2000,"claim":"Revealed calmodulin as a direct negative regulator coupling Ca2+ and Erk crosstalk to SMAD2 linker phosphorylation.","evidence":"Direct binding assays, Xenopus functional assays, and Erk2-dependent phosphorylation analysis","pmids":["11007779"],"confidence":"Medium","gaps":["Mammalian physiological relevance not established","Quantitative contribution to signaling output unclear"]},{"year":2004,"claim":"Demonstrated cooperative SMAD2/SMAD3 dose-dependent function in craniofacial and endodermal development through genetic interaction.","evidence":"Compound heterozygous Smad2/Smad3 knockout mice with histology and expression analysis","pmids":["15183723"],"confidence":"High","gaps":["Distinct vs redundant target genes not parsed","Molecular basis of endoderm displacement failure unresolved"]},{"year":2006,"claim":"Identified acetylation of Lys19 by p300/CBP/P/CAF as a TGF-β-dependent activating modification that enhances DNA binding via conformational change.","evidence":"In vitro acetylation, acetyl-Lys19 antibody, ChIP, and Lys19 mutagenesis with DNA-binding assays","pmids":["17074756"],"confidence":"High","gaps":["Reversal/deacetylase not identified at the time","Interplay with phosphorylation kinetics not mapped"]},{"year":2007,"claim":"Showed SMAD2 protein stability is set by ubiquitin/proteasome turnover, with endoglin potentiating signaling by reducing degradation.","evidence":"Endoglin siRNA, ubiquitination assays, protein vs mRNA Westerns, and reporter assays","pmids":["17058229"],"confidence":"Medium","gaps":["E3 ligase mediating degradation not identified here","Direct vs indirect endoglin effect unresolved"]},{"year":2009,"claim":"Placed SMAD2/3 as transcriptional drivers of myostatin/TGF-β-induced muscle atrophy, with inhibition driving mTOR-dependent hypertrophy.","evidence":"Dominant-negative constructs in adult myofibers with muscle mass and mTOR analysis","pmids":["19357234"],"confidence":"Medium","gaps":["Direct atrophy target genes not defined here","SMAD2 vs SMAD3 contribution not separated"]},{"year":2010,"claim":"Reframed SMAD2 as a counter-regulatory brake on SMAD3-driven fibrosis, restraining Smad3 phosphorylation and COL1A2 promoter binding.","evidence":"Conditional tubular Smad2 KO (UUO model), overexpression rescue, and Smad3 ChIP on COL1A2","pmids":["20595680"],"confidence":"High","gaps":["Molecular mechanism of SMAD2 restraint on SMAD3 phosphorylation not fully defined","Generalizability across fibrotic tissues addressed only later"]},{"year":2013,"claim":"Identified Araf as a linker-region kinase (Ser253) that accelerates degradation of activated SMAD2, antagonizing Nodal/SMAD2 mesendoderm induction.","evidence":"In vitro kinase assay, S253 mutagenesis, co-IP, and zebrafish araf knockdown","pmids":["23591895"],"confidence":"High","gaps":["Mammalian Araf-SMAD2 axis relevance not established","Degradation machinery downstream of linker phosphorylation not fully defined"]},{"year":2013,"claim":"Showed PAK4 dually regulates SMAD2 — kinase-independent blockade of C-terminal phosphorylation and kinase-dependent degradation under HGF.","evidence":"Co-IP, kinase assays, DN/CA PAK4 constructs, ubiquitin-proteasome degradation assays, and gastric cancer IHC","pmids":["23934187"],"confidence":"Medium","gaps":["Single lab; reciprocal in vivo validation limited","Switch between the two mechanisms not quantitatively defined"]},{"year":2015,"claim":"Defined opposing SMAD2 vs SMAD3 roles in dendritic cell TGF-β autoinduction, with SMAD2 loss producing tolerogenic, TGF-β-high DCs.","evidence":"Conditional Smad2-deficient DCs, TGF-β expression assay, and colitis model","pmids":["26141582"],"confidence":"Medium","gaps":["Direct promoter mechanism of SMAD2 repression of TGF-β not mapped","Single-lab in vivo immune model"]},{"year":2015,"claim":"Established SMAD2 (not SMAD3) as a transcriptional repressor at the BECN1 promoter controlling endothelial autophagy.","evidence":"SMAD2 siRNA, BECN1 reporter assays, endoglin perturbation, and autophagy quantification","pmids":["25931117"],"confidence":"Medium","gaps":["Corepressor identity at BECN1 not defined","Direct binding to BECN1 promoter element not mapped"]},{"year":2016,"claim":"Defined non-redundant SMAD2 vs SMAD3 promoter logic in chondrogenesis, with SMAD2 recruiting Hdac4 and SMAD3 recruiting Ski at distinct Ihh SBEs.","evidence":"Cartilage-specific Smad2 KO and global Smad3 KO, ChIP for Smad2/3 and Hdac4, and SBE mutagenesis","pmids":["27741240"],"confidence":"High","gaps":["Determinants of differential SBE selectivity not structurally defined","Generalization to other promoters unclear"]},{"year":2016,"claim":"Explained the functional divergence of SMAD2 and SMAD3 by their distinct basal localization and oligomerization, with SMAD3's linker impairing SMAD4 binding.","evidence":"Subcellular fractionation, immunofluorescence, SMAD4 co-IP, and ChIP-seq","pmids":["26905010"],"confidence":"Medium","gaps":["Structural basis of localization difference not resolved here","Single-lab observations"]},{"year":2017,"claim":"Identified CCT6A as a direct SMAD2 binder that switches TGF-β output from tumor-suppressive SMAD2 to prometastatic SMAD3 programs.","evidence":"Co-IP, SMAD2/CCT6A knockdown, transcriptional and invasion/metastasis assays in NSCLC","pmids":["28375158"],"confidence":"Medium","gaps":["Mechanism of SMAD2 suppression by CCT6A not biochemically resolved","Single-lab models"]},{"year":2017,"claim":"Genetically dissected SMAD2 vs SMAD3 in cardiac fibrosis, showing SMAD3 (not SMAD2) drives fibroblast-mediated fibrosis.","evidence":"Fibroblast-specific inducible Smad2 or Smad3 KO in pressure-overload model","pmids":["28891814"],"confidence":"High","gaps":["Molecular target genes distinguishing the two not detailed","SMAD2's positive role in this context limited"]},{"year":2018,"claim":"Provided structural basis for combinatorial cofactor binding, mapping MH2 hydrophobic patches used cooperatively/competitively by FOXH1 and SKI.","evidence":"X-ray crystallography of SMAD3-FOXH1 and SMAD2-SKI complexes","pmids":["29588413"],"confidence":"High","gaps":["Full repertoire of patch-binding cofactors not catalogued","Dynamics of cooperative/competitive switching not captured"]},{"year":2018,"claim":"Resolved linker-region phospho-site selectivity, linking specific residues and kinases to distinct GAG-synthesis gene programs downstream of thrombin.","evidence":"Site-directed mutagenesis of individual linker residues and selective kinase inhibitors with gene expression readout","pmids":["30423352"],"confidence":"Medium","gaps":["Direct vs indirect transcriptional links not all established","Single-lab system"]},{"year":2019,"claim":"Overturned the view that SMAD2 cannot bind DNA, showing E3-insert conformation enables direct DNA binding while SMAD2 (unlike SMAD3) requires signaling for promoter recruitment.","evidence":"Crystal structure of SMAD2-DNA, biochemical DNA binding, ChIP-seq, and mouse mesendoderm genetics","pmids":["31582430"],"confidence":"High","gaps":["Genome-wide determinants of SMAD2 vs SMAD3 site selection not fully mapped","Conformational trigger for E3 insert not defined"]},{"year":2019,"claim":"Identified WWP2 N-terminal isoform as a regulator of SMAD2 nucleocytoplasmic shuttling and transcriptional activity relevant to cardiac fibrosis.","evidence":"Co-IP, nuclear translocation assays, WWP2 N-terminal deletion transgenic mice, and cardiac fibroblast assays","pmids":["31399586"],"confidence":"Medium","gaps":["Whether WWP2 ubiquitinates SMAD2 directly not resolved","Single-lab mechanism"]},{"year":2020,"claim":"Defined SIRT2 as a SMAD2 deacetylase (K451) that promotes SMURF2-dependent ubiquitination and degradation, coupling deacetylation to turnover.","evidence":"Co-IP, in vitro deacetylation with site mapping, ubiquitination assays, SMURF2 epistasis, and renal Sirt2 KO","pmids":["37777567"],"confidence":"High","gaps":["Interplay of K451 with activating Lys19 acetylation not integrated","Tissue scope beyond kidney unclear"]},{"year":2020,"claim":"Showed LSD1 co-recruits with phospho-SMAD2/3 to EMT gene promoters, priming activation/repression through a nuclear oxidative wave.","evidence":"ChIP for co-recruitment, confocal/mass spectrometry for DNA oxidation, and co-IP","pmids":["32697292"],"confidence":"Medium","gaps":["Causal link between DNA oxidation and transcription not fully established","Single-lab"]},{"year":2020,"claim":"Identified MED1 as a SMAD2 interactor whose loss stabilizes SMAD2 to promote SMAD2-dependent EMT and melanoma metastasis.","evidence":"Co-IP, ubiquitination assays, MED1 perturbation with EMT/migration readouts, and metastasis model","pmids":["35131256"],"confidence":"Medium","gaps":["Mechanism by which MED1 promotes SMAD2 degradation unresolved","Single-lab"]},{"year":2020,"claim":"Showed mutant FOXL2C134W gains capacity to assemble a FOXL2/SMAD4/SMAD2-3 complex on a novel hybrid motif driving EMT gene expression.","evidence":"Co-IP, ChIP-seq for hybrid motif, and SMAD4/SMAD2-3 knockdown epistasis","pmids":["32641411"],"confidence":"Medium","gaps":["SMAD2-specific vs SMAD3-specific contribution not separated","Single-lab"]},{"year":2021,"claim":"Showed SMAD2 can drive terminal myogenic differentiation and myogenin expression independently of TGF-β receptor activation.","evidence":"SMAD2 KO/overexpression in primary myoblasts and satellite-cell-specific Smad2 KO with regeneration assays","pmids":["33462116"],"confidence":"Medium","gaps":["How receptor-independent SMAD2 is activated not defined","Direct myogenin promoter interaction not mapped"]},{"year":2021,"claim":"Linked creatine/MPS1-mediated SMAD2/3 phosphorylation to Snail/Slug induction and metastasis.","evidence":"MPS1 inhibition, GATM knockdown, phospho-SMAD2/3 Westerns, and orthotopic metastasis models","pmids":["33811821"],"confidence":"Medium","gaps":["Direct MPS1 phosphorylation site on SMAD2 not mapped","Single-lab"]},{"year":2021,"claim":"Showed fluid-shear-stress control of SMAD2/3 acts at nuclear translocation via MEKK3/Klf2 and CDK2-dependent linker phosphorylation, decoupling phosphorylation from nuclear entry.","evidence":"EC-specific ALK5 deletion, nuclear translocation imaging, and CDK2/Klf2 inhibition in flow models","pmids":["34504019"],"confidence":"Medium","gaps":["Mechanistic link between linker phosphorylation and translocation block not detailed","Single-lab"]},{"year":2022,"claim":"Linked mitochondrial dysfunction to MAPK-mediated SMAD2 phosphorylation enhancing ALK5-SMAD2 signaling in endothelial vascular pathology.","evidence":"Endothelial Smad2 KO rescuing three mitochondrial KO models, ALK5 inhibition, and fractionation","pmids":["36496409"],"confidence":"Medium","gaps":["Mitochondrial SMAD2 localization mechanism only partly supported","Single-lab"]},{"year":2023,"claim":"Established PPM1A as a direct SMAD2 phosphatase whose loss sustains p-SMAD2 and protects cartilage, with rescue by TGF-β/SMAD2 inhibition.","evidence":"Co-IP, PPM1A conditional KO in DMM model, and pharmacological rescue with SD-208","pmids":["36752205"],"confidence":"High","gaps":["Selectivity of PPM1A for SMAD2 vs SMAD3 not detailed","Structural basis of recognition unresolved"]},{"year":2024,"claim":"Defined a Thbs1→TGF-β-SMAD2/3→ATF4→ALP/UPS axis driving muscle atrophy, with myofiber Smad2/3 deletion conferring protection.","evidence":"Myofiber-specific Smad2/Smad3 double KO, Thbs1 and ATF4 mouse models, and ALP/UPS activity assays","pmids":["38678560"],"confidence":"High","gaps":["SMAD2 vs SMAD3 individual contribution within the axis not separated","Direct ATF4 promoter regulation by SMAD2 not mapped"]},{"year":null,"claim":"How the combinatorial code of SMAD2 post-translational modifications (Lys19/K451 acetylation, multi-site linker phosphorylation), E3-insert conformation, and cofactor patch occupancy is integrated to produce context-specific, SMAD2- vs SMAD3-divergent transcriptional outputs remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking modification state to genome-wide site selection","Determinants of SMAD2 vs SMAD3 promoter partitioning incompletely defined","In vivo turnover regulators integrating SIRT2/SMURF2/WWP2/MED1 not reconciled"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,9,16,22,32]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[9,22]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,4]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,4,17]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2,3,17,22]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[9,23,25]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,4,22]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,6,8,16,28]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,9,16,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,12,19,20,26]}],"complexes":["SMAD2/SMAD3/SMAD4 heterotrimer","SMAD2-SKI corepressor complex","FOXL2C134W/SMAD4/SMAD2-3 complex"],"partners":["SMAD4","SMAD3","SARA","SKI","FOXH1","PPM1A","SIRT2","CCT6A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15796","full_name":"SMAD family member 2","aliases":["JV18-1","Mad-related protein 2","hMAD-2","Mothers against decapentaplegic homolog 2","MAD homolog 2","Mothers against DPP homolog 2"],"length_aa":467,"mass_kda":52.3,"function":"Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD2/SMAD4 complex, activates transcription. Promotes TGFB1-mediated transcription of odontoblastic differentiation genes in dental papilla cells (By similarity). Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. May act as a tumor suppressor in colorectal carcinoma (PubMed:8752209)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q15796/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SMAD2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SMAD2","total_profiled":1310},"omim":[{"mim_id":"621305","title":"CARDIAC MESODERM ENHANCER-ASSOCIATED NONCODING RNA; CARMN","url":"https://www.omim.org/entry/621305"},{"mim_id":"620847","title":"BONE MORPHOGENETIC PROTEIN 8A; BMP8A","url":"https://www.omim.org/entry/620847"},{"mim_id":"619657","title":"CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 8, WITH OR WITHOUT HETEROTAXY; CHTD8","url":"https://www.omim.org/entry/619657"},{"mim_id":"619656","title":"LOEYS-DIETZ SYNDROME 6; LDS6","url":"https://www.omim.org/entry/619656"},{"mim_id":"619516","title":"BIFUNCTIONAL APOPTOSIS REGULATOR; BFAR","url":"https://www.omim.org/entry/619516"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Primary cilium transition zone","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SMAD2"},"hgnc":{"alias_symbol":["MADR2","JV18-1"],"prev_symbol":["MADH2"]},"alphafold":{"accession":"Q15796","domains":[{"cath_id":"3.90.520.10","chopping":"8-18_38-82_111-170","consensus_level":"medium","plddt":87.1015,"start":8,"end":170},{"cath_id":"2.60.200.10","chopping":"265-453","consensus_level":"high","plddt":95.4893,"start":265,"end":453}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15796","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15796-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15796-F1-predicted_aligned_error_v6.png","plddt_mean":77.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMAD2","jax_strain_url":"https://www.jax.org/strain/search?query=SMAD2"},"sequence":{"accession":"Q15796","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15796.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15796/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15796"}},"corpus_meta":[{"pmid":"9311995","id":"PMC_9311995","title":"TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9311995","citation_count":943,"is_preprint":false},{"pmid":"8752209","id":"PMC_8752209","title":"MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8752209","citation_count":792,"is_preprint":false},{"pmid":"28891814","id":"PMC_28891814","title":"Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28891814","citation_count":772,"is_preprint":false},{"pmid":"9865696","id":"PMC_9865696","title":"SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9865696","citation_count":766,"is_preprint":false},{"pmid":"8980228","id":"PMC_8980228","title":"MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8980228","citation_count":650,"is_preprint":false},{"pmid":"19357234","id":"PMC_19357234","title":"Smad2 and 3 transcription factors control muscle mass in adulthood.","date":"2009","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19357234","citation_count":389,"is_preprint":false},{"pmid":"17340614","id":"PMC_17340614","title":"A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17340614","citation_count":320,"is_preprint":false},{"pmid":"8756346","id":"PMC_8756346","title":"A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway.","date":"1996","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8756346","citation_count":311,"is_preprint":false},{"pmid":"20595680","id":"PMC_20595680","title":"Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis.","date":"2010","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/20595680","citation_count":310,"is_preprint":false},{"pmid":"23139211","id":"PMC_23139211","title":"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23139211","citation_count":276,"is_preprint":false},{"pmid":"9620846","id":"PMC_9620846","title":"Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9620846","citation_count":250,"is_preprint":false},{"pmid":"18809571","id":"PMC_18809571","title":"Redundant roles of SMAD2 and SMAD3 in ovarian granulosa cells in vivo.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18809571","citation_count":160,"is_preprint":false},{"pmid":"26141582","id":"PMC_26141582","title":"Smad2 and Smad3 Inversely Regulate TGF-β Autoinduction in Clostridium butyricum-Activated Dendritic Cells.","date":"2015","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/26141582","citation_count":156,"is_preprint":false},{"pmid":"10535967","id":"PMC_10535967","title":"Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10535967","citation_count":142,"is_preprint":false},{"pmid":"8971158","id":"PMC_8971158","title":"Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8971158","citation_count":139,"is_preprint":false},{"pmid":"10490821","id":"PMC_10490821","title":"Smad2 and Smad4 gene mutations in hepatocellular carcinoma.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10490821","citation_count":137,"is_preprint":false},{"pmid":"29392890","id":"PMC_29392890","title":"A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3.","date":"2018","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/29392890","citation_count":135,"is_preprint":false},{"pmid":"33811821","id":"PMC_33811821","title":"Creatine promotes cancer metastasis through activation of Smad2/3.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33811821","citation_count":126,"is_preprint":false},{"pmid":"26905010","id":"PMC_26905010","title":"Smad2 and Smad3 have differential sensitivity in relaying TGFβ signaling and inversely regulate early lineage specification.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26905010","citation_count":103,"is_preprint":false},{"pmid":"17074756","id":"PMC_17074756","title":"The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17074756","citation_count":100,"is_preprint":false},{"pmid":"17058229","id":"PMC_17058229","title":"Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling.","date":"2007","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17058229","citation_count":99,"is_preprint":false},{"pmid":"28375158","id":"PMC_28375158","title":"CCT6A suppresses SMAD2 and promotes prometastatic TGF-β signaling.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28375158","citation_count":92,"is_preprint":false},{"pmid":"29899418","id":"PMC_29899418","title":"Linc00462 promotes pancreatic cancer invasiveness through the miR-665/TGFBR1-TGFBR2/SMAD2/3 pathway.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29899418","citation_count":87,"is_preprint":false},{"pmid":"31582430","id":"PMC_31582430","title":"Structural basis for distinct roles of SMAD2 and SMAD3 in FOXH1 pioneer-directed TGF-β signaling.","date":"2019","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/31582430","citation_count":79,"is_preprint":false},{"pmid":"10634606","id":"PMC_10634606","title":"TGF-beta receptor expression and smad2 localization are cell density dependent in fibroblasts.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10634606","citation_count":72,"is_preprint":false},{"pmid":"32802182","id":"PMC_32802182","title":"CircCDK14 protects against Osteoarthritis by sponging miR-125a-5p and promoting the expression of Smad2.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32802182","citation_count":68,"is_preprint":false},{"pmid":"34504019","id":"PMC_34504019","title":"Activation of Smad2/3 signaling by low fluid shear stress mediates artery inward remodeling.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34504019","citation_count":64,"is_preprint":false},{"pmid":"24925688","id":"PMC_24925688","title":"Opposing roles for Smad2 and Smad3 in peritoneal fibrosis in vivo and in vitro.","date":"2014","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24925688","citation_count":62,"is_preprint":false},{"pmid":"31399586","id":"PMC_31399586","title":"WWP2 regulates pathological cardiac fibrosis by modulating SMAD2 signaling.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31399586","citation_count":59,"is_preprint":false},{"pmid":"9288786","id":"PMC_9288786","title":"Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9288786","citation_count":57,"is_preprint":false},{"pmid":"27741240","id":"PMC_27741240","title":"Smad2 and Smad3 Regulate Chondrocyte Proliferation and Differentiation in the Growth Plate.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27741240","citation_count":54,"is_preprint":false},{"pmid":"27129272","id":"PMC_27129272","title":"Smad2/3 Proteins Are Required for Immobilization-induced Skeletal Muscle Atrophy.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27129272","citation_count":54,"is_preprint":false},{"pmid":"24795273","id":"PMC_24795273","title":"Physiological and excessive mechanical compression of articular cartilage activates Smad2/3P signaling.","date":"2014","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/24795273","citation_count":54,"is_preprint":false},{"pmid":"10767528","id":"PMC_10767528","title":"Cloning and characterization of zebrafish smad2, smad3 and smad4.","date":"2000","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10767528","citation_count":53,"is_preprint":false},{"pmid":"23934187","id":"PMC_23934187","title":"Oncogenic PAK4 regulates Smad2/3 axis involving gastric tumorigenesis.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23934187","citation_count":53,"is_preprint":false},{"pmid":"9503010","id":"PMC_9503010","title":"Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-beta and activin signal transduction pathway.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9503010","citation_count":49,"is_preprint":false},{"pmid":"33202380","id":"PMC_33202380","title":"NEAT1/miR-200b-3p/SMAD2 axis promotes progression of melanoma.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33202380","citation_count":46,"is_preprint":false},{"pmid":"32641411","id":"PMC_32641411","title":"Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32641411","citation_count":46,"is_preprint":false},{"pmid":"11007779","id":"PMC_11007779","title":"Calmodulin differentially modulates Smad1 and Smad2 signaling.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11007779","citation_count":46,"is_preprint":false},{"pmid":"24530597","id":"PMC_24530597","title":"Pin1 induction in the fibrotic liver and its roles in TGF-β1 expression and Smad2/3 phosphorylation.","date":"2014","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/24530597","citation_count":43,"is_preprint":false},{"pmid":"15183723","id":"PMC_15183723","title":"Smad2 and Smad3 coordinately regulate craniofacial and endodermal development.","date":"2004","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15183723","citation_count":42,"is_preprint":false},{"pmid":"30401983","id":"PMC_30401983","title":"ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30401983","citation_count":41,"is_preprint":false},{"pmid":"21883378","id":"PMC_21883378","title":"Cell biology of Smad2/3 linker region phosphorylation in vascular smooth muscle.","date":"2012","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21883378","citation_count":38,"is_preprint":false},{"pmid":"32850796","id":"PMC_32850796","title":"The Role of SMAD2/3 in Human Embryonic Stem Cells.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32850796","citation_count":37,"is_preprint":false},{"pmid":"31665064","id":"PMC_31665064","title":"BMP3 suppresses colon tumorigenesis via ActRIIB/SMAD2-dependent and TAK1/JNK signaling pathways.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31665064","citation_count":37,"is_preprint":false},{"pmid":"12634305","id":"PMC_12634305","title":"Developmental and stage-specific expression of Smad2 and Smad3 in rat testis.","date":"2003","source":"Journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/12634305","citation_count":37,"is_preprint":false},{"pmid":"25775035","id":"PMC_25775035","title":"HEB associates with PRC2 and SMAD2/3 to regulate developmental fates.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25775035","citation_count":37,"is_preprint":false},{"pmid":"32210722","id":"PMC_32210722","title":"MSTN Mutant Promotes Myogenic Differentiation by Increasing Demethylase TET1 Expression via the SMAD2/SMAD3 Pathway.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32210722","citation_count":36,"is_preprint":false},{"pmid":"32179057","id":"PMC_32179057","title":"The role of Smad2 and Smad3 in regulating homeostatic functions of fibroblasts in vitro and in adult mice.","date":"2020","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/32179057","citation_count":36,"is_preprint":false},{"pmid":"9197523","id":"PMC_9197523","title":"MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma.","date":"1997","source":"Japanese journal of cancer research : Gann","url":"https://pubmed.ncbi.nlm.nih.gov/9197523","citation_count":35,"is_preprint":false},{"pmid":"33649832","id":"PMC_33649832","title":"MMP11 promotes the proliferation and progression of breast cancer through stabilizing Smad2 protein.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33649832","citation_count":33,"is_preprint":false},{"pmid":"32226309","id":"PMC_32226309","title":"USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32226309","citation_count":33,"is_preprint":false},{"pmid":"38678560","id":"PMC_38678560","title":"Thbs1 regulates skeletal muscle mass in a TGFβ-Smad2/3-ATF4-dependent manner.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38678560","citation_count":32,"is_preprint":false},{"pmid":"32697292","id":"PMC_32697292","title":"Targeted DNA oxidation by LSD1-SMAD2/3 primes TGF-β1/ EMT genes for activation or repression.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/32697292","citation_count":32,"is_preprint":false},{"pmid":"29154818","id":"PMC_29154818","title":"MicroRNA-21 promotes wound healing via the Smad7-Smad2/3-Elastin pathway.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29154818","citation_count":32,"is_preprint":false},{"pmid":"39545942","id":"PMC_39545942","title":"Helicobacter pylori promotes gastric cancer progression by activating the TGF-β/Smad2/EMT pathway through HKDC1.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/39545942","citation_count":31,"is_preprint":false},{"pmid":"17729405","id":"PMC_17729405","title":"Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues.","date":"2007","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17729405","citation_count":31,"is_preprint":false},{"pmid":"25931117","id":"PMC_25931117","title":"Endoglin Regulation of Smad2 Function Mediates Beclin1 Expression and Endothelial Autophagy.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25931117","citation_count":30,"is_preprint":false},{"pmid":"36715115","id":"PMC_36715115","title":"RBM15 silencing promotes ferroptosis by regulating the TGF-β/Smad2 pathway in lung cancer.","date":"2023","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36715115","citation_count":30,"is_preprint":false},{"pmid":"30784922","id":"PMC_30784922","title":"A TGFBR2/SMAD2/DNMT1/miR-145 negative regulatory loop is responsible for LPS-induced sepsis.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30784922","citation_count":30,"is_preprint":false},{"pmid":"31732152","id":"PMC_31732152","title":"miR-145-5p attenuates hypertrophic scar via reducing Smad2/Smad3 expression.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31732152","citation_count":29,"is_preprint":false},{"pmid":"23591895","id":"PMC_23591895","title":"Araf kinase antagonizes Nodal-Smad2 activity in mesendoderm development by directly phosphorylating the Smad2 linker region.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/23591895","citation_count":29,"is_preprint":false},{"pmid":"36752205","id":"PMC_36752205","title":"Protein phosphatase PPM1A inhibition attenuates osteoarthritis via regulating TGF-β/Smad2 signaling in chondrocytes.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36752205","citation_count":28,"is_preprint":false},{"pmid":"24105267","id":"PMC_24105267","title":"Smad2 and Smad3 cooperate and antagonize simultaneously in vertebrate neurogenesis.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/24105267","citation_count":28,"is_preprint":false},{"pmid":"25701598","id":"PMC_25701598","title":"TGF-β/Smad2/3 signal pathway involves in U251 cell proliferation and apoptosis.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/25701598","citation_count":28,"is_preprint":false},{"pmid":"29783655","id":"PMC_29783655","title":"GDF11 Modulates Ca2+-Dependent Smad2/3 Signaling to Prevent Cardiomyocyte Hypertrophy.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29783655","citation_count":28,"is_preprint":false},{"pmid":"28146239","id":"PMC_28146239","title":"Combined PI3K/Akt and Smad2 Activation Promotes Corneal Endothelial Cell Proliferation.","date":"2017","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/28146239","citation_count":27,"is_preprint":false},{"pmid":"29749497","id":"PMC_29749497","title":"miR‑486‑5p is upregulated in osteoarthritis and inhibits chondrocyte proliferation and migration by suppressing SMAD2.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29749497","citation_count":27,"is_preprint":false},{"pmid":"33622411","id":"PMC_33622411","title":"SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion.","date":"2021","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33622411","citation_count":26,"is_preprint":false},{"pmid":"32016481","id":"PMC_32016481","title":"SP1/TGF‑β1/SMAD2 pathway is involved in angiogenesis during osteogenesis.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32016481","citation_count":26,"is_preprint":false},{"pmid":"37777567","id":"PMC_37777567","title":"SIRT2 alleviated renal fibrosis by deacetylating SMAD2 and SMAD3 in renal tubular epithelial cells.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37777567","citation_count":26,"is_preprint":false},{"pmid":"17365852","id":"PMC_17365852","title":"Platelets possess functional TGF-beta receptors and Smad2 protein.","date":"2007","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/17365852","citation_count":26,"is_preprint":false},{"pmid":"38424494","id":"PMC_38424494","title":"USF1 transcriptionally activates USP14 to drive atherosclerosis by promoting EndMT through NLRC5/Smad2/3 axis.","date":"2024","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/38424494","citation_count":24,"is_preprint":false},{"pmid":"37739089","id":"PMC_37739089","title":"BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma.","date":"2023","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/37739089","citation_count":24,"is_preprint":false},{"pmid":"15452874","id":"PMC_15452874","title":"Generation of novel conditional and hypomorphic alleles of the Smad2 gene.","date":"2004","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/15452874","citation_count":24,"is_preprint":false},{"pmid":"11172591","id":"PMC_11172591","title":"Somatic alterations of the DPC4 and Madr2 genes in colorectal cancers and relationship to metastasis.","date":"2001","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11172591","citation_count":23,"is_preprint":false},{"pmid":"11304690","id":"PMC_11304690","title":"Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM-1 and DCC tumor suppressor genes on the long arm of chromosome 18.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11304690","citation_count":23,"is_preprint":false},{"pmid":"34925016","id":"PMC_34925016","title":"Inhibition of Sirt2 Alleviates Fibroblasts Activation and Pulmonary Fibrosis via Smad2/3 Pathway.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34925016","citation_count":23,"is_preprint":false},{"pmid":"30423352","id":"PMC_30423352","title":"Individual Smad2 linker region phosphorylation sites determine the expression of proteoglycan and glycosaminoglycan synthesizing genes.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30423352","citation_count":23,"is_preprint":false},{"pmid":"35780861","id":"PMC_35780861","title":"Differential effects of Smad2 and Smad3 in regulation of macrophage phenotype and function in the infarcted myocardium.","date":"2022","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/35780861","citation_count":22,"is_preprint":false},{"pmid":"16607645","id":"PMC_16607645","title":"Inhibition of SMAD2 expression prevents murine palatal fusion.","date":"2006","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/16607645","citation_count":22,"is_preprint":false},{"pmid":"24388384","id":"PMC_24388384","title":"The use of gene activated matrix to mediate effective SMAD2 gene silencing against hypertrophic scar.","date":"2013","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/24388384","citation_count":22,"is_preprint":false},{"pmid":"10420150","id":"PMC_10420150","title":"Expression and mutational analysis of the MADR2/Smad2 gene in human prostate cancer.","date":"1999","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/10420150","citation_count":21,"is_preprint":false},{"pmid":"29588413","id":"PMC_29588413","title":"Hydrophobic patches on SMAD2 and SMAD3 determine selective binding to cofactors.","date":"2018","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/29588413","citation_count":21,"is_preprint":false},{"pmid":"33149556","id":"PMC_33149556","title":"Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway.","date":"2020","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33149556","citation_count":21,"is_preprint":false},{"pmid":"32464258","id":"PMC_32464258","title":"Bovine lactoferrin enhances osteogenesis through Smad2/3 and p38 MAPK activation.","date":"2020","source":"Journal of oral biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/32464258","citation_count":21,"is_preprint":false},{"pmid":"32733385","id":"PMC_32733385","title":"Differential Role of Smad2 and Smad3 in the Acquisition of an Endovascular Trophoblast-Like Phenotype and Preeclampsia.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32733385","citation_count":20,"is_preprint":false},{"pmid":"9328171","id":"PMC_9328171","title":"Smad4 (homolog of human DPC4) and Smad2 (homolog of human JV18-1): candidates for murine lung tumor resistance and suppressor genes.","date":"1997","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/9328171","citation_count":19,"is_preprint":false},{"pmid":"12183405","id":"PMC_12183405","title":"No effects of Smad2 (madh2) null mutation on malignant progression of intestinal polyps in Apc(delta716) knockout mice.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12183405","citation_count":19,"is_preprint":false},{"pmid":"32709857","id":"PMC_32709857","title":"LINC00266-1/miR-548c-3p/SMAD2 feedback loop stimulates the development of osteosarcoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32709857","citation_count":18,"is_preprint":false},{"pmid":"36496409","id":"PMC_36496409","title":"Mitochondrial dysfunction induces ALK5-SMAD2-mediated hypovascularization and arteriovenous malformations in mouse retinas.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36496409","citation_count":18,"is_preprint":false},{"pmid":"26365350","id":"PMC_26365350","title":"Follistatin-like 1 attenuates differentiation and survival of erythroid cells through Smad2/3 signaling.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26365350","citation_count":18,"is_preprint":false},{"pmid":"37940881","id":"PMC_37940881","title":"Exosomal circCOL1A1 promotes angiogenesis via recruiting EIF4A3 protein and activating Smad2/3 pathway in colorectal cancer.","date":"2023","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/37940881","citation_count":17,"is_preprint":false},{"pmid":"32055218","id":"PMC_32055218","title":"Myostatin Increases Smad2 Phosphorylation and Atrogin-1 Expression in Chick Embryonic Myotubes.","date":"2019","source":"The journal of poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/32055218","citation_count":16,"is_preprint":false},{"pmid":"34432647","id":"PMC_34432647","title":"GDF-8 stimulates trophoblast cell invasion by inducing ALK5-SMAD2/3-mediated MMP2 expression.","date":"2021","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34432647","citation_count":16,"is_preprint":false},{"pmid":"19556713","id":"PMC_19556713","title":"Atorvastatin Increases Endoglin, SMAD2, Phosphorylated SMAD2/3 and eNOS Expression in ApoE/LDLR Double Knockout Mice.","date":"2009","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/19556713","citation_count":16,"is_preprint":false},{"pmid":"34638474","id":"PMC_34638474","title":"Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34638474","citation_count":16,"is_preprint":false},{"pmid":"35131256","id":"PMC_35131256","title":"MED1 Downregulation Contributes to TGFβ-Induced Metastasis by Inhibiting SMAD2 Ubiquitination Degradation in Cutaneous Melanoma.","date":"2022","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35131256","citation_count":16,"is_preprint":false},{"pmid":"33462116","id":"PMC_33462116","title":"SMAD2 promotes myogenin expression and terminal myogenic differentiation.","date":"2021","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33462116","citation_count":15,"is_preprint":false},{"pmid":"30280598","id":"PMC_30280598","title":"Dicer deficiency in proximal tubules exacerbates renal injury and tubulointerstitial fibrosis and upregulates Smad2/3.","date":"2018","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30280598","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52303,"output_tokens":10172,"usd":0.154745,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20627,"output_tokens":8886,"usd":0.162642,"stage2_stop_reason":"end_turn"},"total_usd":0.317387,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"MADR2/SMAD2 is directly phosphorylated by the TGF-β receptor complex on C-terminal serines. Interaction requires activation of receptor I (TβRI) by receptor II (TβRII), mediated by the receptor I kinase. Mutation of the phosphorylation sites generates a dominant-negative MADR2 that stably associates with receptors and fails to accumulate in the nucleus in response to TGF-β.\",\n      \"method\": \"In vitro phosphorylation assay, dominant-negative mutagenesis, nuclear accumulation assay, co-immunoprecipitation with receptors\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro phosphorylation by receptor complex, mutagenesis of phosphorylation sites, functional readout of nuclear accumulation and transcription; replicated across multiple experimental approaches in a landmark paper\",\n      \"pmids\": [\"8980228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MADR2/SMAD2 is specifically regulated by TGF-β and not bone morphogenetic proteins. Missense mutations found in colorectal carcinomas are inactivating for TGF-β signaling.\",\n      \"method\": \"Biochemical signaling assays, functional analysis of cancer-derived point mutations\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical specificity demonstrated, functional inactivation of cancer-derived mutations confirmed, replicated concept across multiple labs\",\n      \"pmids\": [\"8752209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Madr2/SMAD2 is a mesoderm inducer that responds to activin signaling; activin stimulation enhances nuclear concentration of Madr2 in Xenopus ectoderm. The C-terminal domain can activate downstream components independently, while an N-terminal repressive domain anchors the protein in the cytoplasm in the absence of signal.\",\n      \"method\": \"Xenopus ectoderm functional assay, lacZ/Madr2 fusion protein nuclear localization analysis, domain deletion experiments\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiment tied to functional consequence (mesoderm induction), domain dissection experiment, activin-dependent nuclear translocation shown\",\n      \"pmids\": [\"8756346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Smad2 and Smad3 interact with the kinase-deficient TGF-β type I receptor after it is phosphorylated by TβRII kinase. TGF-β1 induces phosphorylation of Smad2 and Smad3, and Smads 2 and 3 form heteromeric complexes with Smad4 after TβR activation. Smad2, Smad3 and Smad4 accumulate in the nucleus upon TGF-β1 treatment and show synergistic effects in transcriptional reporter assays.\",\n      \"method\": \"Co-immunoprecipitation in transfected COS cells, immunofluorescence nuclear localization, transcriptional reporter assay (PAI-1 promoter), dominant-negative Smad3\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, nuclear translocation imaging, functional transcriptional readout, dominant-negative epistasis, replicated across multiple cell lines\",\n      \"pmids\": [\"9311995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SARA (Smad anchor for receptor activation), a FYVE domain protein, directly interacts with Smad2 and Smad3 and recruits Smad2 to the TGF-β receptor by controlling subcellular localization. Phosphorylation of Smad2 induces dissociation from SARA with concomitant Smad2/Smad4 complex formation and nuclear translocation. SARA mutations causing mislocalization of Smad2 inhibit TGF-β-dependent transcriptional responses.\",\n      \"method\": \"Yeast two-hybrid/pulldown, co-immunoprecipitation, subcellular localization assay, dominant-negative SARA mutant functional assay, transcriptional reporter assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding demonstrated, localization-function linkage established by mislocalization mutant, phosphorylation-driven complex switching shown, multiple orthogonal methods\",\n      \"pmids\": [\"9865696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HGF and EGF, signaling through receptor tyrosine kinases, can also induce phosphorylation and nuclear translocation of Smad2 via kinase(s) downstream of MEK1. A mutation in Smad2 that blocks TGF-β signaling also blocks HGF signal transduction, placing Smad2 as a common effector of both RTK and TGF-β receptor pathways.\",\n      \"method\": \"Epitope-tagged Smad2 phosphorylation and nuclear translocation assay, SMAD-dependent reporter gene activation, dominant-negative Smad2 epistasis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — nuclear translocation and reporter assay in single lab, functional mutation epistasis shown; replicated in part but pathway placement is via single mutation\",\n      \"pmids\": [\"9620846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SMAD2 is required in extraembryonic tissues for generation of the anterior-posterior axis and gastrulation. Postgastrulation Smad2-deficient embryos show malformation of head structures, abnormal embryo turning, and cyclopia, and expression of the homeobox gene Hex (earliest A-P polarity marker) is absent in Smad2-deficient embryos.\",\n      \"method\": \"Smad2 null mouse knockout, chimeric embryo rescue by wild-type extraembryonic tissues, in situ hybridization for Hex expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function in vivo with defined molecular readout (Hex expression), tissue-specific rescue experiment, multiple developmental phenotypes characterized\",\n      \"pmids\": [\"10535967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Calmodulin directly binds to two distinct conserved regions in Smad2 and inhibits Smad2 function in Xenopus embryos. Calmodulin binding to Smad2 inhibits subsequent Erk2-dependent linker region phosphorylation of Smad2, and vice versa, indicating cross-talk between Ca2+/calmodulin, RTK/Erk, and TGF-β pathways at the level of Smad2.\",\n      \"method\": \"Direct binding assay (calmodulin-Smad interaction), Xenopus embryo functional assay, structure-function analysis with domain deletions, Erk2-dependent phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated, functional inhibition in vivo, cross-talk mechanism via phosphorylation shown; single lab with multiple methods\",\n      \"pmids\": [\"11007779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Smad2 and Smad3 function cooperatively in craniofacial and endodermal development. Compound heterozygous mice (one allele each of Smad2 and Smad3 null) show craniofacial defects and hepatic phenotypes due to defects in the definitive endoderm, including failure to displace visceral endoderm.\",\n      \"method\": \"Genetic epistasis via compound heterozygous mouse knockout, histology, gene expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with defined tissue-specific readout, compound heterozygous rescue and phenotyping\",\n      \"pmids\": [\"15183723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Smad2 acetylation by coactivators p300, CBP, and P/CAF occurs in a TGF-β-dependent manner. The major acetylated residue in both the long and short isoforms of Smad2 is Lys19 in the MH1 domain. Acetylation of Lys19 in the short isoform improves DNA binding activity in vitro, enhances association with target promoters in vivo, and augments transcriptional activity by inducing a conformational change making the DNA-binding domain accessible.\",\n      \"method\": \"In vitro acetylation assay, acetyl-Lys19-specific antibody detection of endogenous acetylation, chromatin immunoprecipitation (ChIP), site-directed mutagenesis of Lys19, DNA binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic acetylation by named writers (p300, CBP, P/CAF), mutagenesis of the modified residue, endogenous modification confirmed, ChIP for promoter binding, conformational change mechanistically supported\",\n      \"pmids\": [\"17074756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Endoglin increases Smad2 protein levels by decreasing ubiquitination and proteasome-dependent degradation, thereby stabilizing Smad2 and potentiating TGF-β-Smad2 signaling to increase eNOS expression in endothelial cells. Smad2-specific signaling is upregulated by endoglin and downregulated when endoglin is knocked down with siRNA.\",\n      \"method\": \"siRNA knockdown of endoglin, dominant-negative Smad2, ubiquitination assay, Western blot for Smad2 protein levels vs. mRNA, eNOS and PAI-promoter reporter assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination/degradation mechanism demonstrated, promoter reporter assays, siRNA knockdown; single lab, multiple methods\",\n      \"pmids\": [\"17058229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Smad2 and Smad3 are transcription factors downstream of myostatin/TGF-β that induce a muscle atrophy program in adult myofibers. Smad2/3 inhibition promotes muscle hypertrophy in a manner independent of satellite cells but partially dependent on mTOR signaling.\",\n      \"method\": \"In vivo genetic perturbation with dominant-negative constructs in adult myofibers, muscle mass measurement, mTOR signaling analysis\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function with defined atrophy/hypertrophy phenotype, pathway epistasis with mTOR; single lab\",\n      \"pmids\": [\"19357234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Smad2 protects against TGF-β/Smad3-mediated renal fibrosis. Conditional deletion of Smad2 from kidney tubular epithelial cells markedly enhanced fibrosis, and Smad2 deletion promoted fibrosis through enhanced TGF-β/Smad3 signaling evidenced by greater Smad3 phosphorylation, nuclear translocation, and binding of Smad3 to the COL1A2 promoter. Conversely, overexpression of Smad2 attenuated TGF-β1-induced Smad3 phosphorylation.\",\n      \"method\": \"Conditional Smad2 knockout in tubular epithelial cells (unilateral ureteral obstruction model), Smad2 overexpression, Smad3 ChIP on COL1A2 promoter, Western blot for phospho-Smad3\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined molecular mechanism (Smad3 phosphorylation and ChIP-promoter binding), overexpression reciprocal experiment, in vivo and in vitro orthogonal validation\",\n      \"pmids\": [\"20595680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Araf kinase directly binds to and phosphorylates Smad2 in the linker region with Ser253 being indispensable, in a Mek/Erk-independent manner. This linker phosphorylation attenuates Smad2 signaling by accelerating degradation of activated Smad2 and antagonizes mesendoderm induction by Nodal/Smad2 in zebrafish embryos.\",\n      \"method\": \"Direct in vitro kinase assay (Araf phosphorylates Smad2), site-directed mutagenesis of S253, co-immunoprecipitation (Araf-Smad2 interaction), zebrafish araf knockdown with mesendoderm phenotype, degradation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis identifying specific phosphorylation site, direct binding, in vivo loss-of-function epistasis, degradation mechanism shown\",\n      \"pmids\": [\"23591895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PAK4 interacts with Smad2/3 in a kinase-independent manner and blocks TGF-β1-induced phosphorylation of Smad2 at Ser465/467, attenuating Smad2/3 transcriptional activity. Additionally, PAK4 phosphorylates Smad2 on Ser465 in a kinase-dependent manner under HGF stimulation, leading to ubiquitin-proteasome-dependent degradation of Smad2.\",\n      \"method\": \"Co-immunoprecipitation (PAK4-Smad2/3 interaction), kinase assay, dominant-negative and constitutively active PAK4 constructs, ubiquitin-proteasome degradation assay, immunohistochemistry of gastric cancer tissues\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction and kinase activity shown, two distinct mechanisms (kinase-independent blocking and kinase-dependent phosphorylation/degradation) demonstrated; single lab\",\n      \"pmids\": [\"23934187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Smad2 negatively regulates TGF-β autoinduction in dendritic cells, whereas Smad3 is necessary for robust TGF-β expression. Smad2-deficient DCs expressed higher concentrations of TGF-β and were tolerogenic for colitis models.\",\n      \"method\": \"Smad2-deficient dendritic cells (conditional knockout), TGF-β expression assay, colitis model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined molecular and cellular phenotype; single lab with in vitro and in vivo validation\",\n      \"pmids\": [\"26141582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Smad2 and Smad3 regulate chondrocyte proliferation and differentiation in the growth plate by repressing Ihh expression. Smad2 and Smad3 bind to distinct Smad binding elements (SBEs) in the Ihh promoter, mediating assembly of distinct repressive complexes: TGF-β induces association of Hdac4 with Smad2 (but not Smad3) on the Ihh promoter, while Ski is recruited by Smad3.\",\n      \"method\": \"Cartilage-specific Smad2 conditional KO and global Smad3 KO mice, ChIP analysis of Smad2/3 and Hdac4 on Ihh promoter, SBE mutagenesis, primary chondrocyte TGF-β treatment\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with phenotype, ChIP demonstrating differential Smad2/3 binding at specific SBEs, SBE mutagenesis, corepressor association defined by ChIP; multiple orthogonal methods\",\n      \"pmids\": [\"27741240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Smad3 preferentially localizes to the nucleus in unstimulated cells (sequestered from membrane signaling), while Smad2 remains predominantly cytoplasmic and is a more sensitive TGF-β transducer. The unique linker region of Smad3 impairs its ability to oligomerize with Smad4 upon agonist stimulation.\",\n      \"method\": \"Subcellular fractionation, immunofluorescence localization, Smad4 co-immunoprecipitation assay, ChIP-seq for target gene binding specificity\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence, oligomerization assay; single lab, multiple methods\",\n      \"pmids\": [\"26905010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Smad2/3 proteins are required for immobilization-induced skeletal muscle atrophy. Immobilization elevates Smad2/3 protein (not mRNA) levels in muscle. Muscle-specific Smad2/3-deficient mice are significantly resistant to denervation-induced atrophy, and expression of atrogenes Atrogin-1 and MuRF1 does not increase in Smad2/3-deficient muscles following denervation. IGF1 signaling inhibits Smad2/3 protein accumulation.\",\n      \"method\": \"Muscle-specific Smad2/3 double knockout mice, denervation/immobilization model, atrogene expression analysis, IGF1 receptor activity assessment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific double KO with defined atrophy phenotype, molecular mechanism (atrogene induction) established, protein vs. mRNA distinction made; multiple in vivo and in vitro experiments\",\n      \"pmids\": [\"27129272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCT6A directly binds SMAD2 and suppresses its function, switching TGF-β-induced transcriptional responses from tumor-suppressive (Smad2-dependent) to prometastatic (Smad3-dependent) in NSCLC cells.\",\n      \"method\": \"Co-immunoprecipitation (CCT6A-SMAD2 direct interaction), SMAD2/CCT6A knockdown, transcriptional response assay, NSCLC cell invasion/metastasis assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding confirmed by co-IP, SMAD2 functional suppression by CCT6A shown; single lab, multiple cell/animal models\",\n      \"pmids\": [\"28375158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Fibroblast-specific deletion of Smad3, but not Smad2, markedly reduces pressure overload-induced cardiac fibrosis. Deletion of Smad2/3 from tissue-resident fibroblasts attenuates injury-induced cellular expansion and expression of fibrosis-mediating genes.\",\n      \"method\": \"Fibroblast- and myofibroblast-specific inducible Cre knockout mice for Smad2 or Smad3, pressure overload model, fibrosis quantification, gene expression analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with defined in vivo fibrosis phenotype; Smad2 vs. Smad3 dissected; replicated across fibrosis models\",\n      \"pmids\": [\"28891814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The crystal structures of SMAD3 in complex with FOXH1 and SMAD2 in complex with corepressor SKI reveal that the MH2 domains of SMAD2 and SMAD3 have multiple hydrophobic patches on their surfaces that serve as cofactor interaction interfaces. Cofactors tether to various subsets of these patches in a cooperative or competitive manner to control TGF-β signaling output.\",\n      \"method\": \"X-ray crystallography of SMAD3-FOXH1 complex and SMAD2-SKI complex, structural analysis of MH2 hydrophobic patches\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures of SMAD2-SKI and SMAD3-FOXH1 complexes, structural basis for differential cofactor binding defined\",\n      \"pmids\": [\"29588413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Biochemical and structural evidence shows that SMAD2 binding to DNA depends on the conformation of the E3 insert (a structural element unique to SMAD2 previously thought to render SMAD2 unable to bind DNA). SMAD2 remains predominantly cytoplasmic in the basal state and binds SMAD4 upon Nodal TGF-β signaling to join SMAD3:FOXH1 at target promoters. SMAD3 is recruited by FOXH1 to mesendoderm differentiation gene promoters independently of TGF-β signals, while SMAD2 requires signaling.\",\n      \"method\": \"Crystal structure of SMAD2-DNA complex, biochemical DNA binding assay, ChIP-seq for SMAD2 and SMAD3 binding at mesendoderm promoters, SMAD3 and FOXH1 co-IP, mouse mesendoderm differentiation genetic experiments\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with E3 insert conformation, biochemical DNA binding assay, ChIP-seq for in vivo binding, genetic in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"31582430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"WWP2 (E3 ubiquitin ligase, N-terminal isoform) interacts with SMAD2 and mediates TGF-β1-induced nucleocytoplasmic shuttling and transcriptional activity of SMAD2. TGF-β1 stimulation promotes nuclear translocation of WWP2 N-terminal isoforms and their interaction with SMAD2.\",\n      \"method\": \"Co-immunoprecipitation of WWP2-SMAD2, nuclear translocation assay, transgenic mouse with WWP2 N-terminal deletion (reduced cardiac fibrosis), primary cardiac fibroblast assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction by co-IP, nuclear translocation shown, in vivo KO phenotype; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"31399586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SIRT2 directly interacts with and deacetylates SMAD2 at lysine 451, promoting its ubiquitination and degradation. Loss of SMAD specific E3 ubiquitin protein ligase 2 (SMURF2) abolishes SIRT2-induced ubiquitination and degradation of SMAD2. SIRT2 also reduces phosphorylation, acetylation and nuclear localization of SMAD2.\",\n      \"method\": \"Co-immunoprecipitation, in vitro deacetylation assay with site identification (K451), ubiquitination assay, SMURF2 knockdown epistasis, conditional Sirt2 KO in renal tubule epithelial cells\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical deacetylation with specific lysine identified, ubiquitination mechanism and E3 ligase (SMURF2) identified, in vivo KO phenotype corroborates; multiple orthogonal methods\",\n      \"pmids\": [\"37777567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LSD1 is recruited together with phosphorylated SMAD2/3 to promoters of TGF-β1-activated and repressed EMT genes within 30-90 minutes of TGF-β1 treatment, triggering a nuclear oxidative wave. This LSD1-pSMAD2/3 complex primes TGF-β1/EMT target genes for activation or repression through targeted DNA oxidation.\",\n      \"method\": \"ChIP (LSD1 and pSMAD2/3 co-recruitment to promoters), confocal microscopy and mass spectrometry for nuclear oxidative wave, co-immunoprecipitation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for co-recruitment at promoters, mass spectrometry for DNA oxidation; single lab, multiple methods\",\n      \"pmids\": [\"32697292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMAD2 interacts with MED1 and MED1 downregulation protects SMAD2 from ubiquitin-mediated degradation, stabilizing SMAD2 and promoting TGF-β/SMAD2-dependent EMT and metastasis in cutaneous melanoma.\",\n      \"method\": \"Co-immunoprecipitation (MED1-SMAD2 interaction), ubiquitination assay, MED1 knockdown/overexpression with EMT and migration readouts, in vivo metastasis model\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction and ubiquitination mechanism shown; single lab, in vitro and in vivo validation\",\n      \"pmids\": [\"35131256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Creatine promotes cancer metastasis by activating monopolar spindle 1 (MPS1)-mediated phosphorylation of Smad2 and Smad3, leading to upregulation of Snail and Slug expression. MPS1 inhibition suppresses cancer metastasis by downregulating Smad2/3 phosphorylation and downstream Snail/Slug.\",\n      \"method\": \"MPS1 inhibitor treatment, GATM knockdown, Smad2/3 phosphorylation western blot, orthotopic mouse metastasis models\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic inhibition of MPS1 with Smad2/3 phosphorylation readout, in vivo metastasis model; single lab\",\n      \"pmids\": [\"33811821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In the absence of TGF-β signaling, SMAD2 promotes terminal myogenic differentiation and myogenin expression in a TGF-β receptor-independent manner. Knockout of SMAD2 in primary myoblasts produces smaller myotubes with reduced myogenin expression; loss of Smad2 in satellite cells in vivo results in decreased muscle fiber caliber and impaired regeneration.\",\n      \"method\": \"SMAD2 knockout in primary myoblasts, SMAD2 overexpression (signaling-independent constructs), in vivo satellite cell-specific Smad2 KO, muscle regeneration assay\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO and overexpression with defined molecular (myogenin expression) and cellular (myotube size) phenotype, both in vitro and in vivo; single lab\",\n      \"pmids\": [\"33462116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Mitochondrial dysfunction induces MAPKs-mediated phosphorylation of SMAD2 at a mitochondrial localization, leading to enhanced ALK5-SMAD2 signaling in endothelial cells. Genetic deficiency of SMAD2 prevents retinal vessel growth retardation and arteriovenous malformations in mitochondria-deficient mutant mice.\",\n      \"method\": \"Endothelial-specific SMAD2 KO mice, TFAM/COX10/TRX2 endothelial KO models, ALK5 pharmacological inhibition, SMAD2 phosphorylation localization by cell fractionation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO of SMAD2 rescues vascular phenotype across three independent mitochondrial KO models; mechanism (MAPK-mediated mitochondrial SMAD2 phosphorylation) proposed with partial biochemical support; single lab\",\n      \"pmids\": [\"36496409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Low fluid shear stress activates Smad2/3 phosphorylation through ALK5 and Neuropilin-1 (which increases sensitivity to BMP-9). Smad2/3 nuclear translocation and target gene expression (but not phosphorylation) are maximal at low FSS and suppressed at physiological high shear. The MEKK3/Klf2 pathway mediates suppression of Smad2/3 nuclear translocation at high FSS through CDK2-dependent phosphorylation of the Smad linker region.\",\n      \"method\": \"EC-specific ALK5 deletion in carotid ligation model, nuclear translocation immunofluorescence, pharmacological CDK2/Klf2 inhibition, in vitro flow chamber experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EC-specific KO with in vivo vascular phenotype, CDK2-linker phosphorylation mechanism identified; single lab, multiple methods\",\n      \"pmids\": [\"34504019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Individual phosphorylation sites in the Smad2 linker region (Thr220, Ser245, Ser250, Ser255) are selectively phosphorylated by different kinases (JNK, p38, PI3K for Thr220; multiple kinases for serine residues) in response to thrombin, and are linked to the expression of specific proteoglycan/glycosaminoglycan synthesis genes (XT-1, C4ST-1, CHSY-1).\",\n      \"method\": \"Site-directed mutagenesis of individual linker region residues, selective kinase inhibitors, gene expression analysis for GAG synthesis genes\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific residue-kinase linkages defined by mutagenesis and selective inhibitors; single lab, multiple phospho-site/kinase combinations analyzed\",\n      \"pmids\": [\"30423352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Smad2, but not Smad3, acts as a transcriptional repressor upstream of the BECN1 promoter in endothelial cells, regulating autophagy. Endoglin promotes autophagy by impeding Smad2 transcriptional repressor activity, with Smad2 knockdown directly correlating with enhanced beclin1 levels and autophagy.\",\n      \"method\": \"Smad2 siRNA knockdown, BECN1 promoter reporter assay, endoglin overexpression/knockdown, autophagy quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assay identifies SMAD2 as repressor, siRNA knockdown with autophagy readout; single lab, multiple methods\",\n      \"pmids\": [\"25931117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Mutant FOXL2C134W acquires the ability to bind SMAD4 and form a FOXL2C134W/SMAD4/SMAD2/3 complex that binds a novel hybrid DNA motif unique to the mutant. Ablation of SMAD4 or SMAD2/3 strongly reduces FOXL2C134W binding at hybrid sites and decreases expression of associated EMT genes.\",\n      \"method\": \"Co-immunoprecipitation (FOXL2C134W-SMAD4-SMAD2/3 complex), ChIP-seq for hybrid motif binding, siRNA knockdown of SMAD4 and SMAD2/3, chromatin state analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complex formation by co-IP, ChIP-seq for binding sites, knockdown epistasis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"32641411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PPM1A (protein phosphatase magnesium-dependent 1A) directly interacts with phospho-SMAD2 and acts as a phosphatase for SMAD2. PPM1A knockout protects mice from cartilage degeneration in the DMM model by maintaining higher p-SMAD2 levels in chondrocytes; inhibition of TGF-β/SMAD2 signaling (by SD-208) abolishes the protective phenotype of PPM1A-KO mice.\",\n      \"method\": \"Co-immunoprecipitation (PPM1A-pSMAD2 interaction), PPM1A conditional KO mouse with DMM model, pharmacological rescue with SD-208 (TGF-β/SMAD2 inhibitor), PPM1A pharmacological inhibitors (SC, BC-21)\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct interaction confirmed, conditional KO with in vivo phenotype, pharmacological rescue epistasis, PPM1A established as a SMAD2 phosphatase; multiple orthogonal methods\",\n      \"pmids\": [\"36752205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Thbs1 activates TGF-β-Smad2/3 signaling which induces ATF4 expression; Smad2/3 together with ATF4 modulate the autophagy-lysosomal pathway (ALP) and ubiquitin-proteasome system (UPS) to facilitate muscle atrophy. Myofiber-specific deletion of Smad2 and Smad3 antagonizes Thbs1-induced muscle atrophy.\",\n      \"method\": \"Smad2/Smad3 myofiber-specific double KO mice, Thbs1 transgenic mice, ATF4 KO mice, ALP and UPS activity assays, Thbs1 KO denervation/caloric restriction models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific double KO with mechanistic pathway (Smad2/3→ATF4→ALP/UPS) defined, multiple genetic models, Thbs1 KO validation; multiple orthogonal in vivo experiments\",\n      \"pmids\": [\"38678560\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMAD2 is a receptor-regulated transcription factor that is directly phosphorylated on C-terminal serines by the activated TGF-β/activin type I receptor complex (requiring TβRI kinase activation by TβRII); in unstimulated cells, SARA (a FYVE-domain scaffold) anchors SMAD2 at the receptor by direct binding, while calmodulin and nuclear-preferring Smad3 compete for its regulation; upon receptor phosphorylation, SMAD2 dissociates from SARA, forms heterotrimeric complexes with SMAD4 (and SMAD3), and translocates to the nucleus, where its DNA binding is facilitated by a conformational change in its unique E3 insert and enhanced by p300/CBP/P/CAF-mediated acetylation of Lys19; nuclear SMAD2 recruits distinct co-activators (e.g., FOXH1 with SMAD4) or co-repressors (e.g., Hdac4 on the Ihh promoter) depending on context; its activity is attenuated by linker region phosphorylation (by Araf, MAPKs, CDK2), by phosphatases (PPM1A dephosphorylates it), by deacetylation/ubiquitination/degradation mediated by SIRT2/SMURF2, and by interactors such as CCT6A; SMAD2 and SMAD3 have distinct—sometimes opposing—roles in fibrosis (SMAD3 predominantly pro-fibrotic; SMAD2 counter-regulatory), muscle atrophy (both required downstream of myostatin/TGF-β and Thbs1 via ATF4/ALP/UPS), chondrogenesis, embryonic axis formation (Hex expression in extraembryonic tissue), and terminal myogenic differentiation (SMAD2 promotes myogenin independently of TGF-β receptor activation).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SMAD2 is a receptor-regulated transcription factor that transduces TGF-β/activin/Nodal signals from the cell surface to the nucleus to control mesoderm induction, embryonic axis formation, and tissue homeostasis [#0, #2, #6]. Upon activation of the TGF-β type I receptor by the type II receptor kinase, SMAD2 is directly phosphorylated on C-terminal serines; mutation of these sites yields a dominant-negative protein that stays receptor-bound and fails to accumulate in the nucleus [#0, #3]. In unstimulated cells SMAD2 is held cytoplasmic by the FYVE-domain scaffold SARA, which directly binds and recruits it to the receptor, while phosphorylation drives SARA dissociation, heterotrimer formation with SMAD4 (and SMAD3), and nuclear translocation [#4, #17]. In the nucleus, DNA binding depends on the conformation of the SMAD2-specific E3 insert and is enhanced by p300/CBP/P/CAF-mediated acetylation of Lys19 in the MH1 domain, while the MH2 hydrophobic surfaces serve as combinatorial docking sites for cofactors such as FOXH1 and the corepressor SKI [#9, #21, #22]. SMAD2 activity is attenuated by linker-region phosphorylation (Araf, MAPKs, CDK2), by the phosphatase PPM1A, and by deacetylation and ubiquitin-mediated degradation through SIRT2/SMURF2 and interactors including CCT6A [#13, #30, #34, #24, #19]. SMAD2 and SMAD3 carry distinct and often opposing roles: SMAD2 is counter-regulatory in fibrosis (restraining SMAD3-driven collagen induction), both are required for myostatin/TGF-β- and Thbs1-driven muscle atrophy via ATF4/ALP/UPS, and SMAD2 can promote terminal myogenic differentiation independently of receptor activation [#12, #20, #35, #28]. Cancer-derived inactivating mutations in SMAD2 abrogate TGF-β signaling, consistent with a tumor-suppressive role [#1].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established SMAD2 as the direct intracellular substrate of the activated TGF-β receptor, defining the entry point of the signaling cascade.\",\n      \"evidence\": \"In vitro phosphorylation, dominant-negative mutagenesis of C-terminal serines, and nuclear accumulation assays\",\n      \"pmids\": [\"8980228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve heterotrimer composition or DNA-binding mechanism\", \"Phosphatase/turnover regulation unaddressed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined pathway specificity (TGF-β vs BMP) and linked SMAD2 loss-of-function to human cancer through inactivating colorectal carcinoma mutations.\",\n      \"evidence\": \"Biochemical signaling specificity assays and functional analysis of cancer-derived point mutations\",\n      \"pmids\": [\"8752209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which mutations inactivate signaling not structurally defined at the time\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed SMAD2 is a signal-dependent mesoderm inducer whose nuclear accumulation rises with activin, with separable activating and cytoplasmic-anchoring domains.\",\n      \"evidence\": \"Xenopus ectoderm functional assay and lacZ-Madr2 nuclear localization with domain deletions\",\n      \"pmids\": [\"8756346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the cytoplasmic anchor not yet known\", \"Downstream transcriptional partners unidentified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated heteromeric SMAD2/SMAD3/SMAD4 complex formation and cooperative nuclear transcriptional output, defining the effector complex.\",\n      \"evidence\": \"Reciprocal co-IP, immunofluorescence, and PAI-1 reporter assays with dominant-negative Smad3\",\n      \"pmids\": [\"9311995\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the complex not resolved\", \"Promoter recruitment cofactors not identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified SARA as the cytoplasmic anchor that recruits SMAD2 to the receptor, explaining how localization gates signaling.\",\n      \"evidence\": \"Yeast two-hybrid/pulldown, co-IP, mislocalization mutants, and reporter assays\",\n      \"pmids\": [\"9865696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How phosphorylation releases SARA structurally unresolved\", \"SARA regulation upstream not defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Placed SMAD2 as a shared effector of RTK (HGF/EGF) signaling acting through MEK1-downstream kinases, broadening its input beyond TGF-β.\",\n      \"evidence\": \"Phosphorylation/nuclear translocation assays and dominant-negative epistasis\",\n      \"pmids\": [\"9620846\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct kinase downstream of MEK1 not identified\", \"Physiological relevance vs canonical TGF-β input unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Established an in vivo developmental requirement for SMAD2 in extraembryonic tissue for A-P axis formation, linking it to Hex expression.\",\n      \"evidence\": \"Smad2 null mouse knockout, chimeric rescue, and Hex in situ hybridization\",\n      \"pmids\": [\"10535967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets driving axis formation not defined\", \"Cell-autonomous vs non-autonomous contributions only partly resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed calmodulin as a direct negative regulator coupling Ca2+ and Erk crosstalk to SMAD2 linker phosphorylation.\",\n      \"evidence\": \"Direct binding assays, Xenopus functional assays, and Erk2-dependent phosphorylation analysis\",\n      \"pmids\": [\"11007779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mammalian physiological relevance not established\", \"Quantitative contribution to signaling output unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated cooperative SMAD2/SMAD3 dose-dependent function in craniofacial and endodermal development through genetic interaction.\",\n      \"evidence\": \"Compound heterozygous Smad2/Smad3 knockout mice with histology and expression analysis\",\n      \"pmids\": [\"15183723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distinct vs redundant target genes not parsed\", \"Molecular basis of endoderm displacement failure unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified acetylation of Lys19 by p300/CBP/P/CAF as a TGF-β-dependent activating modification that enhances DNA binding via conformational change.\",\n      \"evidence\": \"In vitro acetylation, acetyl-Lys19 antibody, ChIP, and Lys19 mutagenesis with DNA-binding assays\",\n      \"pmids\": [\"17074756\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reversal/deacetylase not identified at the time\", \"Interplay with phosphorylation kinetics not mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed SMAD2 protein stability is set by ubiquitin/proteasome turnover, with endoglin potentiating signaling by reducing degradation.\",\n      \"evidence\": \"Endoglin siRNA, ubiquitination assays, protein vs mRNA Westerns, and reporter assays\",\n      \"pmids\": [\"17058229\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating degradation not identified here\", \"Direct vs indirect endoglin effect unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Placed SMAD2/3 as transcriptional drivers of myostatin/TGF-β-induced muscle atrophy, with inhibition driving mTOR-dependent hypertrophy.\",\n      \"evidence\": \"Dominant-negative constructs in adult myofibers with muscle mass and mTOR analysis\",\n      \"pmids\": [\"19357234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct atrophy target genes not defined here\", \"SMAD2 vs SMAD3 contribution not separated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Reframed SMAD2 as a counter-regulatory brake on SMAD3-driven fibrosis, restraining Smad3 phosphorylation and COL1A2 promoter binding.\",\n      \"evidence\": \"Conditional tubular Smad2 KO (UUO model), overexpression rescue, and Smad3 ChIP on COL1A2\",\n      \"pmids\": [\"20595680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of SMAD2 restraint on SMAD3 phosphorylation not fully defined\", \"Generalizability across fibrotic tissues addressed only later\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified Araf as a linker-region kinase (Ser253) that accelerates degradation of activated SMAD2, antagonizing Nodal/SMAD2 mesendoderm induction.\",\n      \"evidence\": \"In vitro kinase assay, S253 mutagenesis, co-IP, and zebrafish araf knockdown\",\n      \"pmids\": [\"23591895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mammalian Araf-SMAD2 axis relevance not established\", \"Degradation machinery downstream of linker phosphorylation not fully defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed PAK4 dually regulates SMAD2 — kinase-independent blockade of C-terminal phosphorylation and kinase-dependent degradation under HGF.\",\n      \"evidence\": \"Co-IP, kinase assays, DN/CA PAK4 constructs, ubiquitin-proteasome degradation assays, and gastric cancer IHC\",\n      \"pmids\": [\"23934187\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; reciprocal in vivo validation limited\", \"Switch between the two mechanisms not quantitatively defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined opposing SMAD2 vs SMAD3 roles in dendritic cell TGF-β autoinduction, with SMAD2 loss producing tolerogenic, TGF-β-high DCs.\",\n      \"evidence\": \"Conditional Smad2-deficient DCs, TGF-β expression assay, and colitis model\",\n      \"pmids\": [\"26141582\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter mechanism of SMAD2 repression of TGF-β not mapped\", \"Single-lab in vivo immune model\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established SMAD2 (not SMAD3) as a transcriptional repressor at the BECN1 promoter controlling endothelial autophagy.\",\n      \"evidence\": \"SMAD2 siRNA, BECN1 reporter assays, endoglin perturbation, and autophagy quantification\",\n      \"pmids\": [\"25931117\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Corepressor identity at BECN1 not defined\", \"Direct binding to BECN1 promoter element not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined non-redundant SMAD2 vs SMAD3 promoter logic in chondrogenesis, with SMAD2 recruiting Hdac4 and SMAD3 recruiting Ski at distinct Ihh SBEs.\",\n      \"evidence\": \"Cartilage-specific Smad2 KO and global Smad3 KO, ChIP for Smad2/3 and Hdac4, and SBE mutagenesis\",\n      \"pmids\": [\"27741240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of differential SBE selectivity not structurally defined\", \"Generalization to other promoters unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Explained the functional divergence of SMAD2 and SMAD3 by their distinct basal localization and oligomerization, with SMAD3's linker impairing SMAD4 binding.\",\n      \"evidence\": \"Subcellular fractionation, immunofluorescence, SMAD4 co-IP, and ChIP-seq\",\n      \"pmids\": [\"26905010\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of localization difference not resolved here\", \"Single-lab observations\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified CCT6A as a direct SMAD2 binder that switches TGF-β output from tumor-suppressive SMAD2 to prometastatic SMAD3 programs.\",\n      \"evidence\": \"Co-IP, SMAD2/CCT6A knockdown, transcriptional and invasion/metastasis assays in NSCLC\",\n      \"pmids\": [\"28375158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of SMAD2 suppression by CCT6A not biochemically resolved\", \"Single-lab models\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Genetically dissected SMAD2 vs SMAD3 in cardiac fibrosis, showing SMAD3 (not SMAD2) drives fibroblast-mediated fibrosis.\",\n      \"evidence\": \"Fibroblast-specific inducible Smad2 or Smad3 KO in pressure-overload model\",\n      \"pmids\": [\"28891814\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target genes distinguishing the two not detailed\", \"SMAD2's positive role in this context limited\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided structural basis for combinatorial cofactor binding, mapping MH2 hydrophobic patches used cooperatively/competitively by FOXH1 and SKI.\",\n      \"evidence\": \"X-ray crystallography of SMAD3-FOXH1 and SMAD2-SKI complexes\",\n      \"pmids\": [\"29588413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of patch-binding cofactors not catalogued\", \"Dynamics of cooperative/competitive switching not captured\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved linker-region phospho-site selectivity, linking specific residues and kinases to distinct GAG-synthesis gene programs downstream of thrombin.\",\n      \"evidence\": \"Site-directed mutagenesis of individual linker residues and selective kinase inhibitors with gene expression readout\",\n      \"pmids\": [\"30423352\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect transcriptional links not all established\", \"Single-lab system\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Overturned the view that SMAD2 cannot bind DNA, showing E3-insert conformation enables direct DNA binding while SMAD2 (unlike SMAD3) requires signaling for promoter recruitment.\",\n      \"evidence\": \"Crystal structure of SMAD2-DNA, biochemical DNA binding, ChIP-seq, and mouse mesendoderm genetics\",\n      \"pmids\": [\"31582430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide determinants of SMAD2 vs SMAD3 site selection not fully mapped\", \"Conformational trigger for E3 insert not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified WWP2 N-terminal isoform as a regulator of SMAD2 nucleocytoplasmic shuttling and transcriptional activity relevant to cardiac fibrosis.\",\n      \"evidence\": \"Co-IP, nuclear translocation assays, WWP2 N-terminal deletion transgenic mice, and cardiac fibroblast assays\",\n      \"pmids\": [\"31399586\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether WWP2 ubiquitinates SMAD2 directly not resolved\", \"Single-lab mechanism\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined SIRT2 as a SMAD2 deacetylase (K451) that promotes SMURF2-dependent ubiquitination and degradation, coupling deacetylation to turnover.\",\n      \"evidence\": \"Co-IP, in vitro deacetylation with site mapping, ubiquitination assays, SMURF2 epistasis, and renal Sirt2 KO\",\n      \"pmids\": [\"37777567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay of K451 with activating Lys19 acetylation not integrated\", \"Tissue scope beyond kidney unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed LSD1 co-recruits with phospho-SMAD2/3 to EMT gene promoters, priming activation/repression through a nuclear oxidative wave.\",\n      \"evidence\": \"ChIP for co-recruitment, confocal/mass spectrometry for DNA oxidation, and co-IP\",\n      \"pmids\": [\"32697292\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between DNA oxidation and transcription not fully established\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified MED1 as a SMAD2 interactor whose loss stabilizes SMAD2 to promote SMAD2-dependent EMT and melanoma metastasis.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, MED1 perturbation with EMT/migration readouts, and metastasis model\",\n      \"pmids\": [\"35131256\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which MED1 promotes SMAD2 degradation unresolved\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed mutant FOXL2C134W gains capacity to assemble a FOXL2/SMAD4/SMAD2-3 complex on a novel hybrid motif driving EMT gene expression.\",\n      \"evidence\": \"Co-IP, ChIP-seq for hybrid motif, and SMAD4/SMAD2-3 knockdown epistasis\",\n      \"pmids\": [\"32641411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SMAD2-specific vs SMAD3-specific contribution not separated\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed SMAD2 can drive terminal myogenic differentiation and myogenin expression independently of TGF-β receptor activation.\",\n      \"evidence\": \"SMAD2 KO/overexpression in primary myoblasts and satellite-cell-specific Smad2 KO with regeneration assays\",\n      \"pmids\": [\"33462116\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How receptor-independent SMAD2 is activated not defined\", \"Direct myogenin promoter interaction not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked creatine/MPS1-mediated SMAD2/3 phosphorylation to Snail/Slug induction and metastasis.\",\n      \"evidence\": \"MPS1 inhibition, GATM knockdown, phospho-SMAD2/3 Westerns, and orthotopic metastasis models\",\n      \"pmids\": [\"33811821\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct MPS1 phosphorylation site on SMAD2 not mapped\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed fluid-shear-stress control of SMAD2/3 acts at nuclear translocation via MEKK3/Klf2 and CDK2-dependent linker phosphorylation, decoupling phosphorylation from nuclear entry.\",\n      \"evidence\": \"EC-specific ALK5 deletion, nuclear translocation imaging, and CDK2/Klf2 inhibition in flow models\",\n      \"pmids\": [\"34504019\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between linker phosphorylation and translocation block not detailed\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked mitochondrial dysfunction to MAPK-mediated SMAD2 phosphorylation enhancing ALK5-SMAD2 signaling in endothelial vascular pathology.\",\n      \"evidence\": \"Endothelial Smad2 KO rescuing three mitochondrial KO models, ALK5 inhibition, and fractionation\",\n      \"pmids\": [\"36496409\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mitochondrial SMAD2 localization mechanism only partly supported\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established PPM1A as a direct SMAD2 phosphatase whose loss sustains p-SMAD2 and protects cartilage, with rescue by TGF-β/SMAD2 inhibition.\",\n      \"evidence\": \"Co-IP, PPM1A conditional KO in DMM model, and pharmacological rescue with SD-208\",\n      \"pmids\": [\"36752205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity of PPM1A for SMAD2 vs SMAD3 not detailed\", \"Structural basis of recognition unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a Thbs1→TGF-β-SMAD2/3→ATF4→ALP/UPS axis driving muscle atrophy, with myofiber Smad2/3 deletion conferring protection.\",\n      \"evidence\": \"Myofiber-specific Smad2/Smad3 double KO, Thbs1 and ATF4 mouse models, and ALP/UPS activity assays\",\n      \"pmids\": [\"38678560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SMAD2 vs SMAD3 individual contribution within the axis not separated\", \"Direct ATF4 promoter regulation by SMAD2 not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the combinatorial code of SMAD2 post-translational modifications (Lys19/K451 acetylation, multi-site linker phosphorylation), E3-insert conformation, and cofactor patch occupancy is integrated to produce context-specific, SMAD2- vs SMAD3-divergent transcriptional outputs remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking modification state to genome-wide site selection\", \"Determinants of SMAD2 vs SMAD3 promoter partitioning incompletely defined\", \"In vivo turnover regulators integrating SIRT2/SMURF2/WWP2/MED1 not reconciled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 9, 16, 22, 32]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [9, 22]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 4, 17]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 3, 17, 22]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [9, 23, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 4, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 6, 8, 16, 28]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 9, 16, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 12, 19, 20, 26]}\n    ],\n    \"complexes\": [\n      \"SMAD2/SMAD3/SMAD4 heterotrimer\",\n      \"SMAD2-SKI corepressor complex\",\n      \"FOXL2C134W/SMAD4/SMAD2-3 complex\"\n    ],\n    \"partners\": [\n      \"SMAD4\",\n      \"SMAD3\",\n      \"SARA\",\n      \"SKI\",\n      \"FOXH1\",\n      \"PPM1A\",\n      \"SIRT2\",\n      \"CCT6A\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}